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ABSTRACT
PGE2 RECEPTOR SUBSETS MEDIATE HCG REGULATION OF THE
PLASMINOGEN ACTIVATOR/PLASMIN SYSTEM IN PRIMATE
PERIOVULATORY FOLLICLES
Nune Markosyan
Eastern Virginia Medical School and Old Dominion University
Director: Dr. Diane M. Duffy

Elevated follicular prostaglandin E2 (PGE2) levels are necessary for follicle
rupture during ovulation. As the degradation of the follicle wall requires proteolysis, it
was hypothesized that regulation of proteolysis by gonadotropins is PGE2 mediated.
There are four PGE2 receptors: EP1, EP2, EP3 and EP4. To determine which
PGE2 receptors are present in monkey periovulatory follicles, granulosa cells and whole
ovaries were collected 0, 12, 24, and 36 hours after administration of an ovulatory dose of
human chorionic gonadotropin (hCG), or 36 hours after hCG from monkeys that received
the prostaglandin (PG) synthesis inhibitor celecoxib. All EP receptor mRNAs were
present in granulosa cells. By immunofluorescence, EP1 was detectable only 36 hours
after hCG. EP2 and EP3 proteins were present throughout the periovulatory interval. By
western blotting, EP2 and EP3 proteins increased between 0 and 36 hours after hCG. EP4
protein was not detected in periovulatory granulosa cells. An increase in EP2 and EP3
receptor responsiveness was confirmed by measuring elevated cAMP levels in response
to receptor selective agonists. EP1 receptor function, measured as an increase in
intracellular calcium, was present only 36 hours after hCG administration.
To elucidate the role of the ovulatory gonadotropin surge and PGs in the
regulation of periovulatory proteolytic events, the expression of mRNA and protein for

the tissue type plasminogen activator (tPA) and urokinase type plasminogen activator
(uPA) and their inhibitor PAI-1 was measured in granulosa cells. uPA and PAI-1
mRNAs peaked 12 hours and 36 hours after hCG administration respectively. tPA
mRNA decreased 36 hours after hCG. Celecoxib administration had no effect on any of
these mRNAs. By immunofluorescence, tPA and PAI-1 protein expression increased 12
hours after hCG and persisted until 36 hours after hCG. tPA and PAI-1 proteins were not
detectable 36 hours after hCG in celecoxib treated animals. uPA was not detectable in
granulosa cells before and after hCG administration. By in situ zymography,
plasminogen activator (PA) activity was low before hCG administration and detectable
12, 24 and 36 hours after hCG. PA activity was attenuated by pre-incubation with an
anti-tPA antibody. Animals treated for 36 hours with hCG+celecoxib had low ovarian
PA activity. To determine whether PGE2 is the key PG in the regulation of PA family
members, 0 hour granulosa cells were hCG treated with or without PGE2 or EP receptor
selective agonists. tPA protein increased only in the presence of PGE2, the EP2 agonist
or the EP3 agonist. PAI-1 protein was detected in cells cultured with PGE2, the EP1
agonist or the EP3 agonist.
These studies demonstrate that the ovulatory gonadotropin stimulates granulosa
cell EP receptor expression and responsiveness. PGE2, acting through EP2 and EP3
receptors, may mediate the hCG induced increase in tPA proteolytic activity.
Taken together, this study elucidates the mechanisms by which the ovulatory
gonadotropin surge and PGE2 cooperate to regulate proteolysis in the periovulatory
follicle. This information may lead to improved treatments for anovulation or to the
development of new contraceptive options.
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SECTION 1
INTRODUCTION

The release or surge of luteinizing hormone (LH) by the pituitary gland initiates
events in the dominant follicle that will lead ovulation, or the release of a mature oocyte.
Prostaglandins (PGs) produced by the ovarian follicle during the interval between the LH
surge and ovulation (the periovulatory period) are essential for ovulation to occur.
Classical "ablate and replace" experiments have identified PGE2 as the key ovulatory
prostaglandin in several mammalian species.
The actions of PGE2 are mediated by four different receptors: EP1, EP2, EP3 and
EP4. The expression and function of EP receptors have been studied in different tissues
of various species. Successful ovulation requires functional EP receptors to mediate the
ovulatory effects of PGE2. However, very little is known about EP receptors and their
function in the primate ovary and, more specifically, in the granulosa cells of
periovulatory follicles.
Oocyte release at ovulation requires extensive breakdown and remodeling of the
fibrinous and collagenous connective tissue layers of the mammalian follicle. Many
studies suggest that serine proteases of the plasminogen activator (PA) /plasmin system
play a crucial role in follicle wall rupture. Tissue type PA (tPA) and urokinase-type PA
(uPA) act on plasminogen to convert it into the active proteolytic enzyme plasmin, which
degrades extracellular matrix directly or by activation of other proteases. The PA
inhibitor type-1 (PAI-1) is an important regulator of PA dependent proteolysis. The
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synthesis and release of both PAs and their inhibitor are modulated by hormones, growth
factors and cytokines. Studies in various species indicate that the expression and activity
of PAs and their inhibitor may be regulated by the ovulatory surge of gonadotropin to
insure that the follicle wall ruptures just before the expected time of ovulation. However,
several studies suggest that other signaling molecules like PGs may mediate the ability of
gonadotropin to regulate proteolysis in periovulatory follicles. Inhibition of PG synthesis
by intrafollicular indomethacin injection prevented follicle wall rupture while coadministration of indomethacin and PGE2 restored ovulation, supporting a pivotal role
for PGE2 in the degradation of extracellular matrix.
The objectives of this study are the following:
1. Determine which EP receptors are expressed by primate granulosa cells during the
periovulatory period.
2. Determine which EP receptors are able to generate an intracellular response to PGE2
and how EP receptor responsiveness is regulated during the periovulatory period.
3. Determine if the expression of PAs and their inhibitor as well as the activity of
PA/plasmin system are gonadotropin and PGE2 regulated in monkey periovulatory
granulosa cells.
4. Determine which PGE2 receptor(s) mediate the ability of gonadotropin to regulate the
expression and activity of PAs.
Elucidation of the mechanisms of PGE2 action during the periovulatory period and
the effect of PGE2 on proteolytic degradation of the follicle wall may provide necessary
background for the development of new contraceptives that will inhibit ovulation without
affecting the steroid hormonal milieu or the development of the corpus luteum. In

3

addition, this study may identify a mechanism to explain the decreased fertility in women
that receive treatment with drugs including NSAIDs, which inhibit PG synthesis.
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SECTION 2
BACKGROUND
2.1 Follicular Development and Ovulation
In neonatal females, the ovary contains primordial follicles. Each primordial
follicle consists of an oocyte arrested in the prophase of the first meiotic division
surrounded by a monolayer of flat pregranulosa cells. The primordial follicle is separated
from surrounding stroma by a basement membrane (1). The growing oocyte synthesizes
and secretes a mucoid substance containing glycoproteins that forms the zona pellucida,
which separates the oocyte from the granulosa cell layer (2). The primordial follicle lacks
blood vessels inside the basement membrane. The transfer of nutrients to the oocyte
occurs by diffusion through protoplasmic processes from granulosa cells that penetrate
and traverse the zona pellucida to establish contact with the plasma membrane of the
oocyte (3). During follicular development, the oocyte continues to grow, and flattened
granulosa cells are transformed into cuboidal cells to form a primary follicle. By a series
of mitotic divisions, multiple layers of granulosa cells are formed, converting the primary
follicle into a secondary or preantral follicle (4). Concurrent with proliferation of
granulosa cells, stromal cells close to the basement membrane differentiate into theca
interna cells while a portion of theca cells merge with the surrounding stroma and are
transformed into theca externa (5). During subsequent follicular growth, proliferating
granulosa cells secrete proteoglycans and gelatinous materials that form follicular fluid
and transform the secondary follicle into an early antral follicle (6). The antral follicle has
two distinct populations of granulosa cells: mural granulosa cells that line the basement
membrane and cumulus granulosa cells that surround the oocyte (Figure 1). The further
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Figure 1. Antral follicle. The large antral follicle
consists of a fluid filled antrum, an oocyte
surrounded by cumulus granulosa cells and mural
granulosa cells that line basement membrane.
The outer surface of the basement membrane
contacts theca interna cells and blood vessels.
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development of antral follicles is under the control of the pituitary gonadotropins follicle
stimulating hormone (FSH) and LH (5).
At each menstrual cycle, one (or occasionally, more than one) antral follicle from
a cohort of developing follicles stimulated by pituitary gonadotropins matures to become
the dominant follicle that will ovulate. Gonadotropins stimulate the synthesis of
estrogens, androgens and progestins within the ovary. These steroids, along with
gonadotropins, regulate the growth of the antral follicles by inducing receptors necessary
for follicle survival, maturation and ovulation. The rising levels of estrogen produced by
granulosa cells of the dominant follicle induce the anterior pituitary to release an
ovulatory dose of LH known as the LH surge. The latter can lead to as much as a 100fold increase in the circulating level of LH (7). In the early 1970s, it was concluded that
ovulation-inducing hormones consist of a mixture of FSH and LH (8). Other hormones
like chorionic gonadotropin (CG), which has a peptide sequence that is highly
homologous with LH, is commonly used as a substitute for LH (9).
The ovulatory process is initiated at the moment when follicular cells are
stimulated by the LH surge. The period between the LH surge and ovulation is known as
the periovulatory period. The events described below are the changes that take place in
the periovulatory follicle as described by Knobil (4). The follicle basement membrane
breaks down, and the blood vessels penetrate into the follicle, which now is considered a
periovulatory follicle. At this stage, the volume of follicular fluid increases as blood
plasma transudes from the invading blood vessels. Theca cells, endothelial cells and other
stromal elements migrate into granulosa cell layer along with the newly formed
capillaries. Granulosa cells within the follicle stop proliferating and undergo hypertrophy.
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Granulosa cells of mature preovulatory follicles contain some smooth endoplasmic
reticulum, Golgi networks, granular mitochondria, and occasional lipid granules. In the
periovulatory follicle, granulosa cells contain a greater number of lipid granules, which
indicates increased steroidogenesis. After the ovulatory gonadotropin surge, the oocyte
undergoes germinal vesicle breakdown, extrudes the first polar body and proceeds to the
metaphase of the second meiotic cell division. Cumulus granulosa cells around the oocyte
loosen their contacts with each other, secrete hyaluronic acid, and expand into the gel like
matrix. The cumulus-oocyte complex (COC) detaches from the follicle wall; now the
oocyte is ready for ovulation and fertilization. Parallel to above described events, ovarian
stroma undergoes extensive breakdown specifically at the follicle apex. The
periovulatory events culminate in follicle wall rupture and oocyte release, after which the
follicle transforms into a corpus luteum to produce progesterone.
Mammalian ovulation is a unique physiological process that requires the rupture
of multiple layers of healthy tissue at the surface of the ovary. In most mammals, at the
time of ovulation, the site of the imminent rupture on the follicle wall becomes very thin,
almost transparent (10). Following rupture, the luteinizing follicle protrudes through the
ovarian wall forming a so-called ovulatory stigmata. In species such as rabbit and sheep
that form ovulatory stigmata, during the final stages of periovulatory period, the follicle
wall begins to form a bulge on the surface of the ovary, the basement membrane between
the granulosa cell layer and theca interna dissociates and forms invaginations into the
granulosa cell layer (4). Multiple breaks form along the basement membrane, which
allow the blood vessels to penetrate into the follicle. Because of the basement membrane
invagination, the granulosa cell layer and vascular theca layer also dissociate from the
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apex of the stigmata, leaving the thin stigmata wall without blood supply. The thin,
avascular apex becomes almost translucent because of the enzymatic degradation of the
collagenous tissue and finally ruptures, releasing the oocyte with the surrounding
cumulus granulosa cells into the peritoneal cavity. Now, the collapsed postovulatory
follicle is a newly forming corpus luteum (CL) and will become a highly vascularized
endocrine gland that includes both the luteinizing granulosa cells and recently migrated
theca cells (5, 11, 12).
Over the past century, different theories have been proposed to explain the wellorchestrated events that lead to ovulation. Some of these theories were proven wrong, and
others have received some validation by experimental results. However, there is no single
exhaustive theory that will explain all aspects of ovulation, suggesting that ovulation is a
very complex physiological process which probably combines events described in
various theories and requires further investigation for comprehensive understanding.

2.1.1 Smooth muscle theory of ovulation
Initial studies of ovulation were performed mainly in vivo, with observations
made with the naked eye. The early theories about the mechanism of ovulation focused
on the possible role of smooth muscle and the potential for such tissue to create
intrafollicular pressure of sufficient magnitude to cause healthy follicular tissue to
rupture.
The smooth muscle theory of ovulation has been one of the most controversial
issues in the field of reproductive physiology (4). At the beginning of the 20th century,
von Winiwarter and Sainmont provided histological evidence of the presence of smooth
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muscle cells in the cat and human follicle wall. As discussed by Knobil (4), they were
unable to demonstrate that either electrical or chemical stimuli could cause the follicle to
rupture. In 1919, Thomson carried out extensive histological studies and concluded that
rhythmic muscular contractions on an enlarged and vascularized follicle naturally
increase the intrafollicular pressure and cause the follicle to rupture. In 1964, during his
doctoral studies, Espey conducted experiments to investigate the contractile ability of the
cells that were identified as follicular smooth muscle cells. Using transmission electron
microscopy, he examined the distribution of collagenous connective tissue and fibroblasts
in the theca externa of the follicle and verified that follicular collagen fibers were able to
contract when exposed to acidic solutions (13). As he described in a review, Espey found
that strips of sow follicles would contract only in response to HC1, that such contractions
were tetanic in nature (14). He also showed that the tissue would relax only if it was
exposed to alkaline solutions, and that such contractility could be attributed to collagen
fibrils in the thecal layers of the follicle.
The smooth muscle controversy became more intense during the 1970s, when
numerous new reports claimed that smooth muscle activity is an integral part of the
ovulatory process. However, the observation was made that typical smooth-muscle cells
are confined mainly to the hilar and medullary regions of the mammalian ovary (14). At
the time of ovulation, thecal fibroblasts may differentiate into myofibroblasts to facilitate
wound healing, but there is no convincing evidence that such cells have an essential role
in the mechanism of ovulation. It is possible that the rhythmic contractions detected in
the ovaries (15-17) were the consequence of vascular spasms in the blood vessels that
enter the hilar region of the ovary. This could be promoted by an agent like prostaglandin

F2ot (PGF2a), which stimulated contractions of ovarian arterial smooth muscle (18), and
which increased markedly in the ovary during ovulation (19-21). A very recent study
detected cells that stain for SMAa (smooth muscle actin) around individual follicles in
mice (22). These cells formed an interconnected smooth muscle network at the ovarian
level. The apical region of a periovulatory follicle, a putative site of follicle rupture, was
not stained by the SMAa antibody, indicating absence of smooth muscle cells in the
region. In the same study, contractile activity of ovarian tissue was evaluated by an
isometric tension measurement approach. Endothelin-2 instantly induced contraction in
ovarian tissue strips obtained from immature rats primed for superovulation. Endothelin2 mRNA was transiently increased in mural granulosa cells of the periovulatory follicles
just before ovulation (23). Treatment with endothelin-2 receptor B (ETR-B) antagonist
dramatically (>85%) decreased the number of released oocytes in mice, indicating that
endothelin-2 induced contractions may be important for successful ovulation.
In summary, there are still differing opinions about the extent to which smooth
muscle cells are distributed in and around mammalian follicles. Some investigators
continue to believe that the theca externa consists of typical smooth muscle cells. Other
studies report that the theca externa is a matrix of collagenous connective tissue with
fibroblasts, not muscle cells, comprising the cellular component. Until recently, the
consensus was that ovarian contractility is not a necessary feature of the ovulatory
process, but there remains the possibility that some of the fibroblasts begin to
differentiate into myofibroblasts as a ruptured follicle transforms into a corpus luteum.
However, recent studies, which show the importance of the smooth muscle-contracting
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compound endothelin-2 in ovulation, have revived the interest in the smooth muscle
theory of ovulation.

2.1.2 Pressure theory of ovulation
At the beginning of 20th century, additional attention was given to the hypothesis
that an increase in intrafollicular pressure might be responsible for rupture of a mature
ovarian follicle (reviewed by Knobil (4)). In 1921, Wester suggested that some kind of
pressure "necrosis" of the follicular wall was the final cause of rupture. However, the
Guttamacher twins created in sow follicles unusually high intrafollicular pressures of 300
to 350 mm Hg for hours without inducing ovulation. In 1932, Hartman reported that
follicles of pigs, cattle and sheep become less tense a few hours before ovulation, and this
fact does not favor the idea of an increase in intrafollicular pressure as a major stimulator
of ovulation.
Another version of the pressure theory was based on the idea that osmotic
pressure might increase in ovarian follicles near the time of ovulation. In 1958, Zachariae
and Jensen provided support for the osmosis hypothesis by reporting that preovulatory
hyaluronidase activity depolymerized the acid mucopolysaccharides of the follicular
fluid, "resulting in an increase in the intrafollicular colloid-osmotic pressure, increased
volume, and follicular rupture" (reviewed in (4)). However, the presence of a follicular
mucopolysaccharidase was never confirmed, and this theory of ovulation faded.
Later studies excluded the role of hydrostatic pressure in ovulation (10).
Intrafollicular pressure did not increase during ovulation but remained at a relatively
constant 15 to 20 mm Hg that is dependent on the hydrostatic pressure in the extensive
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capillary network of the theca interna. This moderate pressure may play role in the
formation of the ovulatory stigmata, but it is not likely to be the key to ovulation as it
does not explain the majority of observed changes in the follicle structure.

2.1.3 Proteolytic enzyme theory of ovulation
Gradual disappearance of the connective tissue at the stigma and the erosion of
the rupture site described by the early investigators showed that ovulation was not
explosive tearing of the follicle wall. In early studies, Schochet analyzed follicular fluid
from large sow follicles and concluded that the fluid was the source of "a proteolytic
ferment or enzyme" that contributed "to the digestion of the theca folliculi" (reviewed in
(4)). His experiments were never confirmed by others, and it is doubtful that the follicular
fluid is the source of the proteases that degrade the follicle wall. Despite this, Schochet is
usually given credit for the proteolytic enzyme theory of ovulation. Later experiments by
Rugh et al. in 1935 and Kraus et al. in 1947 showed that external application of pepsin
solutions to frog ovaries caused erosion of the follicle wall (reviewed in (4)). In later
studies, it was shown that treatment of preovulatory follicles with a solution of
collagenase caused the follicle wall to dissociate when subjected to only slight tension
(24). It became evident that the follicle wall becomes progressively weaker as the time of
ovulation approaches. Furthermore, treatment of strips of the follicle wall with
proteolytic enzymes mimicked the preovulatory degradation of follicular connective
tissue. Several in vivo and in vitro studies demonstrated that a number of proteases can
degrade the follicle wall, and it was firmly established that the collagenous layers of the
theca externa and tunica albuginea at the apex of a follicle must be degraded before a
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follicle can rupture (14). Subsequent efforts to measure proteolytic enzymes and their
activity in the ovary were not successful until the 1980s. The recent studies on proteolysis
during the periovulatory period are discussed later in the section 2.4.

2.1.4 Ovulation as an inflammatory reaction
Ovulation and inflammation are dynamic processes. Vasodilation, hyperemia,
migration of white blood cells and fibroblasts, an increase in proinflammatory mediators,
and activation of proteolytic enzymes can occur simultaneously; some follow one another
in close sequence.
The ovulatory LH surge causes measurable changes in the ovarian vasculature.
Within a few minutes after gonadotropin stimulation, there is a significant increase in
ovarian blood flow (25). Along with vasodilatation, there is an increase in vascular
permeability in the follicles (26). These vascular changes cause the follicle to become
edematous, and it remains such through the time of follicle rupture (27). Near the time of
ovulation, because of the changes in the vascular system, erythrocytes permeate the walls
of the vessels and form small hemorrhages in the interstitial spaces of the follicle (14).
Thus, LH induces ovarian hyperemia, vasodilation, edema, and even hemorrhages in
ovulatory follicles. In rabbits, 10 hours after mating, there is a conspicuous accumulation
of basophils, other granulocytes, macrophages and thrombocytes in ovulating follicles
(28).
Similar to inflammatory and immune processes, during ovulation there was
degranulation of mast cell histamine (29) and a decrease in the plasma bradykinin
precursor kininogen (30). Both histamine and bradykinin induced ovulation in vitro in
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perfusion systems (30, 31). However, antagonists of HI and H2 histamine receptors
failed to inhibit ovulation in vivo (32, 33). The importance of histamine in ovulation has
not been firmly established. The main question is whether histamine is a causative agent
in the mechanism of ovulation or whether high levels of histamine result from the events
that take place during the ovulatory process. Bradykinin is believed to promote ovulation
by being responsible, at least in part, for the well known increase in prostaglandin
production in periovulatory follicle (31, 34).
Parallel to the events described above, theca cells and fibroblasts migrate into the
granulosa cell layer (14). De-Asua describes fibroblasts as exhibiting either of "two
extreme physiological states: quiescence or active proliferation" (35). Transition to the
proliferating state can be regulated by numerous factors including prostaglandins.
Prostaglandins can mediate the later stages of the inflammatory process by promoting
fibroblast proliferation (35). The latter can also be induced by proteases that stimulate as
much as a 7-fold increase in the frequency of mitosis in fibroblasts (36). Transformed
fibroblasts themselves are a common source of prostaglandins and proteolytic enzymes
like plasminogen activators.
The resemblance of ovulation to an acute inflammatory process was further
reinforced by findings showing that anti-inflammatory drugs can suppress ovulation (37,
38). It became clear that in the mature ovarian follicle the ovulatory gonadotropin surge
induces an elevation in prostaglandin synthesis that is necessary for ovulation to occur
(39-41). These, and many other studies discussed in detail in the next chapter, depict
ovulation as an acute, strictly controlled inflammation-like process with induction of
proteolytic and collagenolytic activities.
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2.2 Prostaglandins and Ovulation
Prostaglandins (PGs) are bioactive eicosanoid lipid messengers that act as
autocrine and paracrine agents. PGs stimulate a wide range of physiological responses in
the cardiovascular, reproductive, urinary, respiratory and gastrointestinal systems.
Commonly associated with inflammatory reactions, PGs can form during immune
reactions and hormonal responses. Typical actions of PGs include the relaxation and
contraction of various types of smooth muscle. PGs also modulate neuronal activity by
either inhibiting or stimulating neurotransmitter release, sensitizing sensory fibers to
noxious stimuli or inducing central actions such as fever generation and sleep induction.
PGs also regulate secretion and motility in the gastrointestinal tract as well as transport of
ions and water in the kidney. PGs are involved in apoptosis, cell differentiation and
oncogenesis. PGs also regulate the activity of blood platelets and are involved in vascular
homeostasis and hemostasis.

2.2.1 Prostaglandin synthesis and catabolism
Unlike many other biologically active substances, PGs are formed immediately
prior to release and are not stored in the body. After biosynthesis, PGs are transported out
of the cell by a PG transporter (42), where they exert their biological function through the
G-protein coupled receptors (43). The inactivation of PGs takes place in the vascular
beds; the lung is the primary site in metabolizing PGs (44). In the pulmonary circulation,
the PGs are enzymatically converted to inactive 15-keto metabolites, and then further
catabolized by p andTOoxidation. Polar catabolites are excreted in the urine and bile.
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PGs are synthesized de novo from membrane-released arachidonic acid (AA) in
response to almost any type of environmental condition that affect the plasma membrane
(45). The biosynthesis of PGs can be divided into three phases: 1. release of the
arachidonic acid from membrane phospholipids by a phospholipase; 2. conversion of
arachidonic acid into an unstable intermediate PGH2 by cyclooxygenase enzymes; and 3.
conversion of PGH2 into various biologically active PGs by a specific terminal synthase
((46), Figure 2).
PG biosynthesis is dependent upon the availability of free arachidonic acid.
Intracellular levels of arachidonic acid are regulated by keeping it esterified until
mobilized by phospholipases (PLA2). There are 4 major groups of PLA2. IB PLA2 is
abundantly present in pancreatic juice (47). The IIA PLA2 (SPLA2) group consists of 10
members, each with a highly conserved catalytic site and Ca

-binding loop. SPLAi

group members are stored in secretory granules of immune cells (46). IVA PLA2 (now
called CPLA201) is activated by submicromolar Ca2+ and by phosphorylation; this enzyme
shows a marked preference for AA over other fatty acids (48, 49). Lastly, iPLA2 activity
is Ca2+ independent (50). Type IV cytosolic PLA2 is the key player in prostaglandin
production within the periovulatory follicle (51).
The next step in PG synthesis is catalyzed by the cyclooxygenase (COX)
enzymes, also known as prostaglandin G/H synthases (52). These are heme-containing
enzymes that catalyze two sequential enzymatic reactions: 1. the bis-oxygenation of AA
leading to production of PGG2 (COX reaction) and 2. reduction of 15-hydroperoxide of
PGG2 leading to formation of PGH2 (hydroperoxidase reaction) (53).
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Three COX enzymes, COX-1, COX-2 and COX-3, are found in mammals. It is
generally considered that COX-1 is constitutively expressed in a wide variety of cells and
plays a housekeeping role (53). COX-2 is normally undetectable, but COX-2 expression
can be induced by a variety of stimuli in certain tissues. A third COX enzyme, named
COX-3, has recently been characterized in dogs, mice and rats, but the expression of a
functional COX-3 in humans is still debated (54).
Constitutive expression of COX-1 versus inducible expression of COX-2 implies
that these enzymes have distinct roles in PG production in different phases of cell
activation (55, 56). In general, COX-1 and COX-2 can be found on the lumenal surfaces
of the ER and nuclear envelope (on both the inner and outer nuclear membranes) (57).
COX-1 dependent PG production is an immediate response, which occurs within several
minutes following a rise in cytoplasmic Ca2+ levels. The delayed PG production over
hours after proinflammatory stimuli is COX-2, but not COX-1, mediated, even when both
enzymes are expressed in the same cells. Induction of the COX-2 enzyme occurs in
response to various stimuli, and the transcriptional regulation of COX-2 significantly
differs according to stimulus and cell type (58). Transcription factors that activate COX-2
transcription include N F - K B , C/EBPp and C/EBP5, AP-1, ATF, CREB and USF-1. The
induction of COX-2 is markedly down-regulated by anti-inflammatory glucocorticoids
(59).
Inhibition of C O X enzyme activity inevitably decreases PG production. In 1971,

John Vane demonstrated that non-steroidal anti-inflammatory drugs (NSAIDs) inhibit PG
synthesis (60). Later studies demonstrated that COX enzymes are the primary target of
NSAIDs, including aspirin, indomethacin, ibuprofen, celecoxib and rofecoxib (61-64).
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There is considerable variation in the relative potencies of NSAIDs to suppress
prostaglandin biosynthesis. Aspirin (acetylsalicylic acid) is a weak inhibitor. Ibuprofen is
a more potent inhibitor than aspirin but is less effective than indomethacin (61). Because
NSAIDs act directly at the COX enzyme to reduce PGH2 synthesis, they rapidly became
the drugs of choice to determine the role of PGs in biological processes including
ovulation. The details of COX-2 regulation and PG synthesis in ovary are discussed in
section 2.2.2.
Bioactive PGE2 is synthesized from PGH2 by specific terminal synthases. In
1999, a member of MAPEG (membrane associated proteins involved in eicosanoid and
glutathione metabolism) superfamily was discovered to have the ability to catalyze the
conversion of PGH2 to PGE2 with strict substrate specificity (65). Following this report,
orthologs (genes in different species that evolved from a common ancestral gene) of this
protein were cloned from several animal species and shown to represent a membranebound form of PGE2 synthase mPGES-1 (66, 67). Immediately after this discovery,
several cytosolic forms of PGES (cPGES (68, 69)) and a second form of membraneassociated PGES, termed mPGES-2 were identified (70).
The catabolism of PGs is initiated by oxidation of the 15(S)-hydroxyl group
catalyzed by 15-hydorxyprostaglandin dehydrogenases (15-PGDHs) (71). As the
resulting 15-ketoprostaglandins possess markedly reduced biological activities, 15PGDHs are considered to be the primary biological inactivators of PGs and other
eicosanoids (72). Type I 15-PGDH is aNAD+ dependent enzyme and is involved
primarily in PG and eicosanoid metabolism (73) whereas type II uses both NADP+ and
NAD+ as cofactors and has broader substrate specificity (74). Although the main
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function of PGDH enzymes is the inactivation of PGs in lung vascular beds (44), recent
studies suggest that 15-PGDH is expressed in combination with PG synthesis enzymes to
fine-tune local PG levels in PG-sensitive tissues.

2.2.2 Prostaglandin synthesis and catabolism in periovulatory follicles
A potential relationship between prostaglandin biosynthesis and ovulation first
emerged during early 1970s when indomethacin-dependent inhibition of ovulation was
initially reported in rats and rabbits (37, 38). For more than 30 years, PGs have been
considered key inflammatory mediators of the ovulatory process inspiring special interest
in reproductive scientists regarding the regulation of PG synthesis (39-41).
In monkey granulosa cells, CPLA2 mRNA expression and PLA2 activity were
increased toward the end of the periovulatory period (51). A cPLA2-selective inhibitor
decreased both PLA2 activity in monkey granulosa cell lysates and PGE2 accumulation in
cultures of human granulosa-lutein cells. Both cPLA2 and SPLA2IIA were expressed by
granulosa cells of rat periovulatory follicles; gonadotropin exposure increased ovarian
PLA2 expression in a manner consistent with a role for these enzymes in periovulatory
PG production (75-77). cPLA2 -/- mice produced small litters, and the pups usually did
not survive (78). These data indicate that CPLA2 is the primary enzyme responsible for
the gonadotropin-stimulated mobilization of arachidonic acid necessary for PG
production by periovulatory follicle.
COX enzymes are expressed in mammalian ovary and play a significant role in
ovulation (52). Levels of COX-1 mRNA in monkey granulosa cells of large antral
follicles did not change across the periovulatory period, and COX-1 protein was not
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detected in the granulosa or theca cells of these same follicles (79). These data suggest
that COX-1 is not a major source of PG in primate periovulatory follicles. In the same
study, COX-2 mRNA levels increased 12 hours after hCG administration and COX-2
protein was detectable in granulosa cells 24 hours after hCG, which was followed by
>200 fold increase in follicular fluid PGE2 levels. COX-2 expression and PG production
are regulated by several pathways in ovarian granulosa cells. A cAMP-response element
has been found in the promoter region of the rat and human COX-2 genes, consistent
with activation of COX-2 gene expression through the LH/hCG receptor (80, 81). Several
in vivo and in vitro studies showed that direct activators of the cAMP dependent protein
kinase A (PKA) including hCG, LH and FSH, are able to upregulate COX-2 expression
in periovulatory granulosa cells in rat, cattle, mare, and non-human primates (79, 80, 82,
83). This results in elevated PG levels in periovulatory follicles, with granulosa cells
being the primary site of PG synthesis ((79, 84, 85) Figure 3). Other mediators can also
modulate COX-2 expression or activity in granulosa cells. Interleukin-1 has been shown
to stimulate COX-2 expression in dispersed cells from the rat ovary and human
luteinizing granulosa cells in vitro (86, 87). These studies established the role of COX-2
as the main COX isozyme responsible for PG synthesis in ovary.
The indomethacin-dependent inhibition of ovulation was initially reported in rats
and rabbits (37, 38) but was subsequently observed in numerous species, including pigs,
sheep, and cows (reviewed in (39, 41)). When indomethacin was administered
intravenously during the ovulatory process, the normally elevated levels of PGE2 and
prostaglandin F2ot (PGF2a) declined significantly within 1 to 2 minutes (88). The ability
of indomethacin to act directly at the ovarian level and block the pre-ovulatory rise in
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follicular PGs was quickly favored as the underlying mechanism responsible for causing
anovulation. Subsequent studies used COX-2 selective inhibitors to prevent ovulation
instead of the nonselective inhibitor indomethacin. NS-398 (COX-2 selective inhibitor)
reduced the synthesis of PGE2 in isolated LH stimulated rat periovulatory follicles
incubated in vitro (89). The highest dose of NS-398 that was used in in vitro studies
decreased the number of ovulation sites when injected subcutaneously 1 hour after hCG
administration. In a similar study in cows, follicular fluid PGE2 concentrations were
decreased in NS-398 treated follicles when compared to follicles treated with diluent, and
nine out of the ten NS-398-injected animals failed to ovulate (90). TheNS-398-injected
follicles developed morphological and endocrine characteristics resembling luteinized,
unruptured follicles. In a random double-blinded study, women whose dominant follicle
had reached 14-16 mm in diameter received 25 mg rofecoxib (COX-2 selective inhibitor)
or placebo orally for 9 days (91). By ultrasound scanning, follicular rupture in the
placebo group was seen within 36 hours of the LH peak while mean rupture day in the
rofecoxib treated group was day 4 after LH surge.
The relationship between PGs and ovulation was further strengthened by studies
in which PGs were able to restore ovulation in indomethacin treated rats, pigs, and rabbits
(92-94). In perfused rat ovary, PGE2 reversed the inhibition of ovulation by
forskolin+indomethacin (95). In rhesus monkeys, on the day before or the day of the LH
surge, intrafollicular injection of indomethacin at final concentration of 10~6 mol/1 or 10"5
mol/1 prevented ovulatory stigmata formation and oocyte release in 4/8 animals ((96)
Figure 4). In contrast, oocytes were not detected in the ruptured, luteinizing follicles from
all three indomethacin+PGE2-injected monkeys Knockout studies in mice confirmed the
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role of PGE2 in ovulation (97). COX-2-/- mice failed to increase intrafollicular PGE2
levels and ovulate in response to PMSG-hCG stimulation. Gonadotropin stimulation and
concurrent treatment with PGE2 resulted in ovulation of COX-2-/- mice comparable to
that in wild type animals. These studies suggest that PGE2 may be important for
successful ovulation in species like rat, mouse and monkey.
Studies presented above have demonstrated the essential role played by
gonadotropin-stimulated COX-2 in ovulation. Although gonadotropins upregulate PG
production via stimulation of PG synthesis enzymes, the intrafollicular PG levels are
fine-tuned by additional gonadotropin regulation of enzymes that are involved in
catabolism of ovarian bioactive PGs.
In female reproductive organs, the PGE2 synthesis enzyme mPGES-1 is highly
expressed in granulosa cells of follicles, the same cell type in which COX-2 is expressed
after stimulation with gonadotropins (98). Monkey granulosa cells expressed mPGES-1,
-2 and cPGES mRNA (85). Only the expression of mPGES-1 mRNA and protein
increased in response to hCG administration, peaking just before the expected time of
ovulation, which suggests that mPGES-1 may be the primary PGES responsible for the
increased follicular PGE2 levels necessary for primate ovulation.
The PG catabolic enzyme NAD+ dependent 15-PGDH is expressed in
periovulatory granulosa cells as detected by RT-PCR, western blotting, and
immunohistochemistry (99, 100). In the non-human primate, PGDH expression and
activity were high in early and mid periovulatory period (99). As a result, despite
increased PG synthesis, there was no PGE2 accumulation in follicular fluid. However, 36
hours after hCG administration, PGDH expression and activity in granulosa cells
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Figure 4. Ovarian morphology and trapped oocytes after follicular injection (96).
Follicles were injected with vehicle (A), 10"5 mol/1 indomethacin (B), or 10~5 mol/1
indomethacin + PGE2 (C). Three days after follicle injection, the ovary was
observed during laparoscopic surgery (A-C). Some ovaries were removed 3 days
after follicle injection, and serial sections were stained with haemotoxylin and eosin
(I). In A-C, the ovulatory stigmata is indicated by an arrow. Histological
examination of ovarian sections (I) shows the presence of luteinizing granulosa cells
(lgc) and stroma (st). Trapped oocytes (arrow) were observed within four out of
eight indomethacin-injected follicles (I). The oocyte of the injected follicle is
surrounded by luteinizing granulosa cells (lgc); the oocyte (asterisk) of a
neighbouring secondary follicle surrounded by ovarian stroma (st) is also shown.
Bar =100 urn. Modified from Duffy et al. ((96), by permission of Oxford University
Press).
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declined whereas COX-2 maintained high expression, which allowed for newly
produced PGE2 to accumulate in follicular fluid. These data suggest that in non-human
primates, PG catabolism and synthesis act in coordinated manner to delay PGE2
elevation until just before expected time of ovulation when it acts to advance the oocyte
release.
The dramatically elevated intrafollicular PGE2 levels immediately before the
expected time of ovulation and the ability of exogenous PGE2 to reverse the anovulatory
effect of COX inhibitors indicate that PGE2 is the key ovulatory PG in several
mammalian species. In this respect, it becomes essential to examine the expression and
function of PGE2 receptors in periovulatory granulosa cells.

2.3 PGE2 Receptors
Most, if not all, tissues respond to PGs. The long list of PG actions include
smooth muscle contraction and relaxation, autonomic neurotransmission, natriuresis,
diuresis, inhibition of platelet adhesiveness and aggregation, redistribution of blood flow
and many others (101). The same PGs may have qualitatively dissimilar effects upon
different tissues. For example, the vasodilator effect of PGE2 on both arterial and venous
vascular beds was one of the first recognized actions of PGE2 (102). However, PGE2
does not uniformly relax smooth muscle and has been shown to constrict trachea, gastric
fundus, and ileum (103). These differential effects of PGE2 provided important initial
evidence for the existence of multiple PGE2 receptors.
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The PGE2 receptors (EP receptors) are members of the G protein coupled family
of receptors, each possessing seven hydrophobic, membrane-spanning a helices (104,
105). The N-terminal segment of these receptors is on the extracellular face, and the Cterminal segment is on the cytosolic face of the plasma membrane. These receptors
transmit signals to intracellular targets via the intermediary action of guanine nucleotidebinding proteins called G proteins (106). The binding of ligands to the extracellular
domain of these receptors induces a conformational change that allows the cytosolic
domain of the receptor to bind to and activate a G protein associated with the inner face
of the plasma membrane (107).
G proteins consist of three subunits, designated a, p, and y (107-109). They are
frequently called heterotrimeric G proteins to distinguish them from other guanine
nucleotide-binding proteins, such as the Ras proteins. The a subunit binds guanine
nucleotides, which regulates G protein activity. In the resting state, a is bound to
guanosine diphosphate (GDP) in a complex with (3 and y. Ligand binding induces a
conformational change in the receptor, such that the cytosolic domain of the receptor
interacts with the G protein and stimulates the release of bound GDP and its exchange for
guanosine triphosphate (GTP). The activated GTP-bound a subunit then dissociates from
P and y, which remain together and function as a Py complex. Both the active GTP-bound
a subunit and the Py complex then interact with their targets to elicit intracellular
responses. The activity of the a subunit is terminated by hydrolysis of the bound GTP,
and the inactive a subunit (now with GDP bound) then re-associates with the Py complex,
ready for the cycle to start anew. Mammalian genome encodes at least 20 different a
subunits, 6 P subunits, and 12 y subunits. Receptors that are coupled with Gas stimulate
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adenylyl cyclase to increase cAMP (109). God coupled receptors inhibit adenylyl cyclase
and inhibit cAMP production, and Gaq stimulates phospholipase C (PLC) to generate IP3
and diacylglycerol as second messengers and increases intracellular Ca2+ (110).
The actions of PGE2 are mediated by four different G-protein coupled receptors:
EP1, EP2, EP3 and EP4 (Figure 5). The EP subtypes differ in tissue distribution, ligandbinding affinity, coupling to intracellular signaling pathways and functions.

2.3.1 TheEPl receptor
The human EP1 receptor cDNA encodes a 402-amino acid polypeptide with a
predicted molecular mass of 41,858 kDa (111). A splice variant of EP1 (rEPl-v) was
cloned from a rat uterus cDNA library (112). The open reading frame of rEPl-v carries a
specific change of 49 amino acids from the middle of transmembrane segment VI to the
COOH terminus; it possesses a transmembrane segment VH-like structure lacking an
intracellular COOH-terminal tail. The rEPl-v receptor retained the ligand binding
activity with affinity and specificity similar to the rEPl receptor but lost the coupling of
signal transduction systems by itself. The generation of second messengers and activation
of signal transduction pathways via EP receptors can be studied using receptor selective
agonists and antagonists.
There is no reported example of a highly selective EP1 agonist. Three compounds
that have proven useful are sulprostone, 17-phenyl-trinor PGE2 and iloprost (103, 113,
114). Sulprostone is most potent at EP3 receptors while 17-phenyl-trinor PGE2 binds and
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activates EP1 and EP3 receptors. Uoprost is more selective for EP1 receptors over EP2
and EP3, but it is also a highly potent PGI2 receptor (IP receptor) agonist, being at least
as potent as PGI2 itself. There are 2 compounds known to posses specific EP1 antagonist
activity: SC-19220 and AH6809 (105). The utility of these antagonists is limited because
SC-19220 has low efficacy and is poorly soluble in water whereas AH6809 is an
effective antagonist of both EP1 and EP2 receptors. A significant stimulus for the
development of pharmacologically and clinically active EP1 receptor antagonists derives
from evidence that the EP1 receptor plays an important role in PG-mediated pain (115)
and that EP1 receptor antagonists have analgesic properties (116).
EP1 receptor is involved in Ca2+mobilization (111, 117). PGE2 caused an
increase in intracellular Ca2+ concentration ([Ca2+]i) in cells expressing the recombinant
murine EP1 receptor (117). It was suggested that EP1 receptors are coupled to Gaq as the
activation of these receptors by receptor specific agonists increased [Ca2+|i, which was
accompanied by modest increases in IP3 generation (117). In another study, PGE2 and
the EP1 selective agonist 17-phenyl-trinor PGE2 induced fibronectin expression in rat
osteoblasts (118). Use of EP1 receptor antisense oligonucleotides, Ca2+ chelaters or PLC
inhibitors attenuated the PGE2-induced fibronectin expression, implying that EP1
receptors are Gaq coupled. In cultured human myometrial cells, PGE2 increased [Ca2+]i
via a pertussis toxin-sensitive pathway, without PLC activation. This [Ca2+]i increase
occurred after an inverse dose-related delay and could be inhibited by either the selective
EP1 antagonist AH6809 or calcium channel blockers (119). In Chinese hamster ovary
cells expressing EP1 receptors, a receptor selective agonist induced an elevation in
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[Ca2+]i that was PLC independent (120). The data from the above described and other
studies suggest that EP1 regulates [Ca2+]i via an unidentified G protein.
The EP1 receptor was originally described as a smooth muscle constrictor (121).
EP1 receptors do not appear to have wide tissue distribution, being most evident in
smooth muscle cells of trachea, the gastrointestinal tract, the uterus, and the bladder (105,
122). Watanabe et al. examined colon carcinogenesis in EP1-/- mice (123). The number
of azoxymethane (potent carcinogen)-induced aberrant foci in the colons of EP-/- mice
decreased by -40% relative to that for wild type mice. An EP1 selective antagonist
reduced the development of aberrant foci in wild-type mice by 30% and the number of
intestinal polyps by ~40%>. In mice, EP1 expression was detected in kidney collecting
ducts and in lung (124). In the rabbit collecting duct, activation of the EP1 receptors
inhibited Na+ and water reabsorption via a Ca2+ coupled mechanism (125). EP1
mediated contractility was detected in human non-pregnant myometrium (126). In the
human ovary, the mRNA for EP1 was present in granulosa-lutein cells (127). The
exposure of granulosa-lutein cells to PGE2 transiently raised [Ca2+]i levels, which could
be prevented by EP1 antagonist AH6809. High resolution immunostaining for EP1
revealed their presence in the nuclear envelope of isolated endothelial cells and in situ in
brain endothelial cells and neurons (128). Stimulation of these nuclear receptors
modulated nuclear calcium and gene transcription.
Despite numerous studies conducted in various species and tissues, the signaling
pathway utilized by EP1 receptors is still unclear. The role of EP1 has been most
extensively studied in the context of smooth muscle contraction and natriuresis.

However, very little is known about EP1 receptor expression, function and regulation in
reproductive systems, including the periovulatory follicle.

2.3.2 The EP2 receptor
The human EP2 receptor cDNA encodes a 358-amino acid polypeptide (129,
130). Mutagenesis studies have demonstrated that the extracellular loop regions of the
EP2 receptor are critical determinants of receptor function. Introduction of point
mutations (131) or creation of receptor chimeras with the EP4 receptor in certain
extracellular regions (132) resulted in a loss of receptor binding and signal transduction.
A single point mutation in the seventh transmembrane domain of the EP2 receptor caused
a selective gain of function of the receptor for prostacyclin analogs (133). Taken together,
these data suggest that both the extracellular sequences and the transmembrane regions
are important for receptor ligand interactions.
EP2 receptors are selectively activated by butaprost and inhibited by AH6809
(133-135). Activation of Gas coupled EP2 receptors by PGE2 or selective agonists leads
to activation of adenylyl cyclase and increase in cAMP production (105, 136). Evidence
of an association between EP2 receptors and cAMP generation has been obtained for
enterocytes and corneal endothelial cells (137, 138). PGE2 and butaprost increased the
cAMP level in a concentration-dependent manner in the Chinese hamster ovary cells
stably expressing EP2 receptor (139).
EP2 is considered a relaxant receptor as it induces smooth muscle relaxation
(135). The precise distribution of the EP2 receptor has been only partially characterized
using Northern blot analysis of mRNA distribution. Such studies reveal a major mRNA
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species of ~3.1 kb that is most abundant in the uterus, lung, and spleen; low levels of
expression were measured in the kidney (130, 134, 139, 140). Lipopolysaccharide (LPS),
an endotoxin of the outer membrane of Gram-negative bacteria, upregulated EP2
expression in a macrophage cell line; this augmentation was completely inhibited by the
simultaneous administration of IFN-y (141). In mouse uterus, EP2 mRNA, which was
hardly detectable before induction of pseudopregnancy, peaked at day 5 of pregnancy and
disappeared quickly thereafter suggesting that EP2 may be involved in the implantation
process (142).
In the mouse ovary, EP2 mRNA was present in both mural and cumulus
granulosa cells 3 hours after hCG injection (143). In human granulosa-lutein cells, EP2
receptor mRNA was detected by RT-PCR (127), and treatment with the EP2 selective
agonist butaprost stimulated both cAMP formation and progesterone production. In
another study, the transcript for the EP2 receptor was localized in the corpus luteum of
the mouse ovary by in situ hybridization, and EP2 protein was expressed in human
corpus luteum as detected by immunohistochemistry (144).
The role of EP2 receptors in vascular responsiveness and blood pressure was
elucidated by knockout studies. Bolus administration of PGE2 produced a transient
hypotensive effect in wild-type mice, whereas it elicited a transient hypertensive response
in EP2-/- mice, suggesting that the vasodilatory action of PGE2 was mediated by EP2
(145). While baseline blood pressure in EP2-/- mice was slightly higher only in females
compared with that of in wild-type females, marked elevation of systolic blood pressure
was observed in EP2-/- mice after they were fed a high-salt diet. These results show that
unopposed vasoconstriction via the EP1 and/or EP3 receptor in EP2-/- mice could

34

contribute to the observed hypertension, particularly when PGE2 production was
increased with a high-salt diet.
The studies in knockout mice elucidated the role of EP2 in reproductive
physiology. Female EP2 -/- mice have reduced litter size (145-147). Hizaki et al.
analyzed the mechanism of this reproductive failure in detail (146). The average number
of embryos at day 19 of pregnancy in EP2-/- mice was 1.5, whereas that in wild-type
mice was 7.1. There was no abnormality of implantation in EP2-/- mice when examined
by intrauterine transfer of wild-type blastocysts. However, EP2-/- females had impaired
ovulation. In wild-type females, PGE2, FSH and dibutyryl cAMP each elicited cumulus
expansion of in vitro. However, in EP2-/- females, only PGE2 failed to elicit cumulus
expansion. Moreover, abortive cumulus expansion was found in EP2-/- females in vivo.
These results demonstrated that PGE2 via the EP2 contributes to cumulus expansion and
that this contribution is indispensable for successful ovulation and fertilization.
Although above-mentioned studies demonstrate the importance of EP2 receptors
for the mouse fertility, very little is known about EP2 receptor expression and regulation
in periovulatory granulosa cells and its role in primate ovulation.

2.3.3 The EP3 receptor
EP3 receptor is unique in that multiple splice variants defined by unique COOHterminal cytoplasmic tails exist in humans, rats, rabbits, mice, and cows (130, 148-151).
During the cloning of EP3 receptor from a bovine adrenal gland cDNA library, it was
found that the EP3 mRNA undergoes alternative splicing in this tissue to produce at least
four EP3 isoforms (EP3A, EP3B, EP3C, and EP3D (151)). The deduced amino acid
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sequences of these isoforms are identical from the amino terminus to the tenth
intracellular amino acids after the seventh transmembrane domain, but differ thereafter.
The four isoforms showed almost identical ligand-binding specificities. Yet these
isoforms couple to different G-proteins to regulate different signaling pathways. The
bovine EP3A receptor couples to God and induces the inhibition of adenylyl cyclase,
whereas the EP3B and EP3C receptors are coupled to Gas and act to increase levels of
cAMP. The EP3D receptor couples to Gaq, in addition to God and Gas, and can evoke a
pertussis toxin-insensitive response (151).
At least three EP3 isoforms (EP3a, EP3|3, and EP3y) are present in the mouse
(150), and homologous splice variants are found in rabbit and human (149, 152). These
isoforms show alternative splicing at the position identical with that found in the bovine
variants. Among the mouse isoforms, EP3a andEP3p couple to the same G-protein, Gai,
and inhibit adenylyl cyclase but are different in their ligand binding affinities and
agonist-induced desensitization (110, 153). The third isoform, EP3y can couple to Gas in
addition to Gai and, at higher agonist concentrations, tends to stimulate adenylyl cyclase
(150). The human EP3 gene formed nine distinct mRNAs encoding eight EP3 isoforms:
EP3-Ia, EP3-Ib, EP3-II, EP3-III, EP3-IV, EP3-V, EP3-VI, EP3e, EP3f (154). All the EP3
splice variants bind PGE2 and the EP3 agonists with similar affinity (155). Signaling
experiments revealed that an EP3 agonist not only inhibited forskolin-induced cAMP
concentrations but also activated mitogen-activated protein kinase in Chinese hamster
ovary cells stably expressing human EP3-V and EP3-VI. These responses were abolished
by treatment with pertussis toxin. In addition, the EP3 agonist increased cAMP
concentrations in EP3VI-expressing cells but was ineffective in EP3V-expressing cells
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(156). Four human EP3 isoforms (EP3-I - EP3-IV) inhibited adenylyl cyclase in an
agonist dependent manner when over-expressed in Chinese hamster ovary cells (157).
The EP3 receptor is expressed in many tissues including kidney, uterus, adrenal
gland, stomach, with Northern analysis showing major mRNA species at -2.4 and -7.0
kb (149, 158-160). EP3 receptor levels are relatively high in mouse, rabbit, and human
kidney, where EP3 is expressed in the tubular epithelium, the thick ascending limb, and
the cortical collecting ducts in the outer medulla (124, 161, 162). In addition, high
expression of EP3 mRNA was found in neurons of the myenteric ganglia (135). In
hypothalamus, EP3 mRNA is expressed in the neurons surrounding the organum
vasculosa lamina terminalis (163).
The EP3 receptor is known as an inhibitory receptor that generally acts as a
constrictor of smooth muscle by decreasing cAMP (105). The significance of EP3
receptor activation to systemic physiology has been significantly advanced by the
availability of mice with targeted disruption of this gene (164, 165). EP3-/- mice exhibit
an impaired febrile (fever generating) response to PGE2, suggesting that EP3 receptor
antagonists could be effective antipyretic (fever reducing) agents. LPS injected
intravenously induced a fever in wild type mice, whereas it failed to induce a fever in
EP3-/- mice (165). It was also confirmed that EP3-/- mice show a normal febrile response
when subjected to a restraint stress, suggesting that EP3 is essential in the febrile
response to LPS while the efferent pathway to fever generation is EP3 independent. Acidinduced mucosal injury was markedly augmented in EP3-/- mice compared with that in
wild type mice and was similar to that in wild type mice pretreated with indomethacin,
suggesting that PGE2 plays a major role via the EP3 receptor in acid induced bicarbonate
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secretion (166). Despite relatively high levels of EP3 receptor in kidney, mice with
targeted disruption of this receptor display only a subtle alteration in urine concentrating
ability (164). In EP3-/- mice, PGE2 failed to induce degranulation of mast cells whereas
in wild-type animals PGE2-induced degranulation was preceded by inhibition of adenylyl
cyclase and increased [Ca2+]i, indicating that at least two EP3 isoforms are responsible
for this PGE2 effect (167).
Despite being a widespread receptor involved in many physiological responses,
EP3 is probably the least studied PGE2 receptor in primates in general and in primate
reproductive tract in particular. To date, there is no information about EP3 receptor
expression and function in primate ovulation.

2.3.4 The EP4 receptor
The human EP4 receptor cDNA encodes a 488-amino acid polypeptide with a
predicted molecular mass of ~53 kDa (129). The EP4 nomenclature is confusing as in
literature dated before 1995 this receptor was referred to as the EP2 receptor (168). Like
the EP2 receptor, the EP4 is a relaxant receptor and signals through Gas and increased
cAMP (129, 130). Structurally, the EP4 receptor has a much longer COOH-terminal
sequence than the EP2 receptor and has been shown to undergo short-term agonistinduced desensitization, which is absent in the EP2 receptor (169, 170). EP4 receptors
may be pharmacologically distinguished from the EP1 and EP3 receptors by their
insensitivity to sulprostone and from EP2 receptors by their insensitivity to butaprost and
relatively selective activation by PGE1-OH (134, 171). Furthermore, [3H]PGE2 binds to
the EP4 receptor with at least 10-fold higher affinity than the EP2 receptor. In addition to
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the human EP4, receptors for mouse, rat, rabbit, and cow have been cloned (129, 134,
168, 172-174).
EP4 is widely distributed throughout the body, and its mRNA is expressed in
almost all mouse tissues examined (174). Its major species of ~3.8kb was detected by
Northern analysis in rabbit thymus, ileum, lung, spleen, adrenal gland, and kidney (173).
It was also found in neurons of the hypothalamus and lower brain stem and in neurons of
the dorsal root ganglion (124, 175). In situ hybridization studies of PGE2 receptors in the
kidney have revealed that the EP4 receptor is expressed in the glomerulus (124, 161, 162,
173). Expression of the EP4 receptor has also been described in venous and arterial beds
of the piglet (105). EP4 mRNA is highly expressed in the gland of the gastric antrum,
indicating that this subtype is involved in PGE2-mediated mucus secretion (176). In
addition, the transcript of this receptor is present in intestinal epithelial cells, especially
those in the upper part of the villi (177). In situ hybridization was also used to examine
the cellular localization of mRNA for EP receptor subtypes in the mouse uterus (142).
The abundance and localization of mRNA for EP4 were found to change considerably in
mice undergoing pseudopregnancy. EP4 mRNA expression sharply increased on day 3 of
pseudopregnancy and was maintained at a high level after day 5. Its expression was
limited to luminal epithelial cells at day 0 but was also expressed in endometrial stromal
cells and the glandular epithelium after induction.
In human ovarian granulosa-luteal cells, EP4 receptor mRNA levels were low or
non-detectable in vivo, but the pro-inflammatory cytokine IL-lp stimulated expression of
EP4 transcripts in concentration- and time-dependent manner (144). In mouse, EP4
mRNA was present in mural and cumulus granulosa cells 3 and 9 hours after hCG
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administration (143). In the oviduct, the expression of EP4 was localized to epithelial
cells. In the rat ovary, most dense immunostaining for EP4 receptor was noticed in
proliferating granulosa cells of the secondary follicles while those of the primordial and
primary follicles were not stained (178).
Similar to their vast distribution in various tissues, a variety of functions is
attributed to EP4 receptors. Although its precise function in kidney glomeruli is yet
uncharacterized, EP4 might contribute to regulation of the renal microcirculation as well
as renin release (161, 162, 173). Vasodilator effect of EP4 activation was described in
piglets (105). Other roles for the EP4 receptor in controlling blood pressure have been
suggested, including the ability to stimulate aldosterone release from zona glomerulosa
cells (179). Because EP4 via Gas is coupled to an increases in cAMP, and PGE2
stimulates chloride secretion and inhibits NaCl absorption in the intestine through the
production of cAMP, it has been suggested that EP4 is involved in these processes and
consequently in PGE2-induced diarrhea (176).
A study using various PG analogs suggested that EP4 is present in the ductus
arteriosus and participates in the dilation of this vessel (180). The presence of the EP4
receptor in ductus was confirmed by in situ hybridization of its mRNA in the mouse (181,
182). The disruption of the EP4 receptor gene resulted in the death of most homozygous
EP4-/- neonates within 3 days after birth, due to marked pulmonary congestion and heart
failure (181,182).
In co-cultures of primary osteoblasts and bone marrow cells that contain
osteoclast precursors, EP4 agonists induced osteoclast formation (183). Although EP4
deficient mice did not show gross skeletal abnormalities, PGE2-induced osteoclast
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formation was impaired in cultured osteoblasts from the EP4-deficient mice and
osteoclast precursors from the spleens of wild type mice. In mouse calvaria cultures, an
EP4 agonist induced cAMP production and the expression of osteoclast differentiation
factor mRNA in osteoblastic cells (184). In calvaria cultured from EP4 knockout mice,
there was marked reduction in bone resorption in response to PGE2. In the same mice,
EP4 agonist failed to induce bone resorption. These findings suggest that PGE2
stimulates bone resorption by a mechanism involving cAMP and osteoclast
differentiation factor, both of which are mediated mainly by EP4.
Very little is known about EP4 receptor function in the reproductive tract. PGE2
has been reported to cause a phenotypic change in decidualization of the endometrium
via elevation of cAMP levels (135). This may be mediated by EP4 receptors in stromal
cells of the endometrium (142). In the rat ovary, EP4 analog injection induced follicle
growth with morphological characteristics similar to that induced by pregnant mare
serum gonadotropin (PMSG) used to stimulate follicle development (178). The data
suggest that signaling through EP4 may be important for follicle growth and maturation.
Molecular cloning of the PGE2 receptors and elucidation of properties such as
ligand binding, signal transduction, and distribution have been pivotal in our
understanding of PG physiology. The importance of each PGE2 receptor can also be
assessed by the use of knockout mice deficient in each receptor in various physiological
and pathophysiological settings. Although extensively studied in species like rabbit,
mouse, and rat, very little is known about the distribution and function of EP receptors in
primates. The fact that PGE2 plays an important role in such a crucial function as
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ovulation makes it especially important to elucidate the location and function of each and
every EP receptor in the primate ovary.

2.4 Proteolysis in Ovulation
The extracellular matrix (ECM) provides a structural scaffold for tissue support
and forms a barrier between tissue compartments. Many physiological and pathological
processes including follicular development, ovulation, embryo implantation,
angiogenesis, wound healing, bone remodeling and tumor invasion require a regulated
turnover of ECM components (185-188). The ECM influences basic cellular processes
such as proliferation, differentiation, migration and adhesion and is, therefore,
fundamental to normal development (187, 189). Due to the complex composition of the
ECM, different proteases with different substrate specificities are required for ECM
remodeling and degradation. As physiological proteolysis often must be spatially
restricted and targeted, the maintenance of health requires strict control of proteolytic
enzymes and their activity. Fine-tuning of proteolytic activity is achieved by establishing
balance between the level of proteases and their inhibitors (190). Ovulation is a vivid
example of a physiological event that requires rigorous regulation of spatially and
temporally restricted proteolysis.
The ovarian follicle is the unit in which an oocyte matures and from which the
oocyte is extruded for subsequent fertilization. Each follicle destined for ovulation must
complete the development and differentiation of its components: oocyte, granulosa cells,
and theca cells. Concurrently, it requires extensive changes in the extracellular
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environment, including angiogenesis and rapid expansion of the follicular size (190,191).
The climactic event of this process is follicle rupture, which occurs at a precise area on
the ovarian surface (the apex), followed by the extrusion of a mature oocyte.
Many cell layers are present at the follicle apex (Figure 6). The ovarian surface
epithelium that comprises the outmost layer of the ovarian wall lines tunica albuginea
(192, 193). The layer below the tunica albuginea contains theca externa and is a dense
collagenous meshwork, which contributes most of the tensile strength of the follicle wall.
The theca interna is a well-vascularized layer between theca externa and the follicular
basal lamina. The follicular side of the basal lamina is lined with mural granulosa cells.
The periovulatory follicle contains three distinct layers of connective tissue (13, 26).
Collagen type IV predominates in the outermost epithelial layer. The tunica albuginea and
theca externa layer consist primarily of collagen types I and III, whose fibrils provide
structural support and tensile strength to the follicle wall (194, 195). The basal lamina,
which separates the vascular theca and avascular granulosa layers, is composed mainly of
collagen type IV, laminin, fibronectin, and proteoglycan (194, 196). The breakdown of
multiple layers at the follicle apex during ovulation requires extensive proteolysis to
degrade these extracellular matrix proteins.
In the ovulatory process, proteolysis has been postulated to degrade the apical
follicular connective tissue, reducing the structural integrity of the follicular wall and
thereby facilitating oocyte release (4). After a long period of conflicting data and
opinions, the overwhelming consensus is that there is an increase in collagenase and
gelatinase activity within the periovulatory follicle before ovulation (197-201). In species
such as rat, mouse, ovine, and human, the increase in proteolytic activity was
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Figure 6. Cell layers and extracellular matrix
proteins present at the follicle apex.
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demonstrated in intact ovaries, follicles, follicular fluid, conditioned medium from
cultured follicles, isolated granulosa cells, and theca cells (202-207). Increased
proteolytic activity was dependent on an LH stimulus (198, 208). There was a 4- to 5-fold
increase in gelatinase and collagenase activity after LH/hCG stimulation in the rat, which
was blocked by inhibiting the endogenous LH surge with Nembutal (198, 200, 208, 209).
In the human, gelatinolytic activity in follicular fluid increased 4-fold between menstrual
cycle day 5 and 13 (205). A similar increase in gelatinolytic activity was observed in
ovine follicles and follicular fluid before ovulation (210, 211). The induction of
proteolytic activity by gonadotropins in many mammalian species indicates that
proteolysis might be a necessary periovulatory event.
A large number of proteases present in the ovary have been suggested to be
involved in the proteolysis of ECM which contributes to ovulation (191,211,212). These
can be classified into several protease families based on their distinct domain structures:
1. Matrix metalloproteases (MMPs) are a large family of zinc containing enzymes
with highly conserved functional domains (213-215).
2. Serine proteases of plasminogen activator/plasmin system (216, 217).
3.

ADAMTSs (a desintegrin and metalloprotease domain with thrombospondin

motifs) are large family of soluble glycoproteins with important roles in cell-to-cell
adhesion and ECM proteolysis (218).
4.

Lysosomal cathepsin-L is a protease, which is a downstream target of the

progesterone receptor (219,220).
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2.4.1 MMPs and TIMPs
MMPs belong to a metzincin family comprised of 25 structurally related members
(221-224) that can be divided into four broad classes: the collagenases, gelatinases,
stromelysins, and membrane type enzymes (225). These proteases exhibit numerous
structural and functional similarities. Common features of the MMP family include: 1)
the presence of zinc in the active site of the catalytic domain, 2) synthesis of the MMPs as
preproenzymes that are secreted in an inactive form, 3) activation of the latent zymogen
in the extracellular space, 4) recognition and cleavage of the ECM by the catalytic domain
of the enzyme, and 5) inhibition of enzyme action by both serum-born and tissue-derived
metalloprotease inhibitors in the extracellular environment.
MMP synthesis and activation are critical points of regulation of ECM
homeostasis (226). The regulation of MMP synthesis can be both tissue- and MMPspecific. MMPs are synthesized as inactive pro-enzymes (pro-MMPs) and secreted into
the extracellular space. Activation of the pro-MMPs in the extracellular space occurs via
proteases, including other MMPs, serine proteases of PA/plasmin system, cysteine
proteases, as well as by nonproteolytic agents such as reactive oxygen species, sulfhydryl
reactive agents, and denaturants. The PA/plasmin system has been proposed to activate
MMPs at the cell surface. Thus, the activation of MMPs can be regulated by a balance
between serine proteases and their inhibitors (222, 223). However, MMPs that are
resistant to serine protease activation, such as MMP-2, are activated via a novel
mechanism involving the MT-MMPs and tissue inhibitor of metalloprotease-2 (223).
In addition to the regulation of MMP synthesis and activation, MMP activity in
the extracellular environment is rigorously controlled by MMP inhibitors. Two major
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classes of MMP inhibitors are generally distinguished, serum born and tissue derived
(227, 228). The serum born inhibitors include the a2-, al-macroglobulins, al-inhibitor-3,
pregnancy zone protein and the ovomacroglobulines (e.g., ovostatin). This class of
inhibitors is a major regulator of collagenolysis in serum and tissue fluids (226). Tissue
inhibitors of metalloproteases, or TIMPs, are locally produced and specifically inhibit
MMPs. In 1975, two separate investigators reported inhibition of collagenolytic activity
by a small molecular weight protein (229, 230). This secreted 29 kDa protein, now called
TIMP-1, was shown to bind and inhibit the active form of MMPs on a 1:1 stoichiometric
basis (231). The N-terminal domain of TIMP binds to and inactivates the catalytic
domain of the MMP. In addition, TIMP blocks the substrate-binding groove of the MMP.
Following the discovery of TIMP-1, three other MMP inhibitors have been identified
including TIMP-2, glycosylated inhibitor TIMP-3, and TIMP-4 (227). There is evidence
indicating that TIMPs, in addition to their ability to regulate MMP activity, regulate
many aspects of cell physiology, including cell growth, angiogenesis and steroidogenesis
(232).

2.4.2 MMPs and TIMPs in ovulation
As a major group of ECM-degrading enzymes, MMPs and TIMPs have been
implicated in local control of ovulation (190, 191, 225). There is a body of morphological
and biochemical studies suggesting an important role for the MMPs in ECM degradation
associated with follicle rupture. Regulation of the expression of MMPs and TIMPs by
ovulatory gonadotropins is one of the indicators of the involvement of these proteases in
the process of ovulation. In the rodent ovary, mRNA expression of MMP-1, MMP-2,
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MMP-9 and MMP-13 all increased after the endogenous LH surge or administration of
hCG to immature PMSG-primed animals (233-235). In the bovine follicle, the expression
of mRNA for MT1-MMP and TIMP-2 was elevated at 6 and 24 hours after the
gonadotropin surge, respectively (236). In the primate, hCG administration increased
granulosa cell expression of mRNA for MMP-1, MMP-2, and MMP-7 within 12 h,
whereas an increase in MMP-9 mRNA occurred at 36 hours after hCG (237). These data
show that the expression of collagenolytic MMPs increases as the ovulation approaches.
The crucial role of the MMPs in follicle rupture was demonstrated by experiments
in which ovulation was blocked by exogenous chemical MMP inhibitors both in vitro and
in vivo, as well as by antibodies against individual MMPs (208, 238-240). In the perfused
rat ovary, the release of oocytes was blocked or inhibited by the metalloprotease
inhibitors phenanthroline or SC 40827 (239). When injected into the antral cavity of
sheep follicles, monoclonal antibodies against MMP-2 suppressed ovulation and caused
formation of luteinized, unruptured follicles (240). It was also shown that ovulation in rat
perfused ovary could be inhibited when MMPs were blocked as late as 7 hours after LH
surge (ovulation occurring at 9-12 hours aftei LH), but no significant inhibition occurred
when the MMP inhibitor was added 9 hours after hCG (241). These data indicate that
MMP-mediated collagenolysis is obligatory for ovulation in species like rat and sheep.
Concomitant with the periovulatory increase in MMPs, LH/hCG stimulates an
increase in mRNA expression and inhibitor activity for some of the TIMPs. TIMP-1
mRNA expression increased after an LH stimulus in the mouse, rat, ewe, non-human
primate, and human (234, 237, 242-247). Simultaneous increases in TIMPs and MMPs
have been reported in numerous tissues and are believed to maintain proteolytic
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homeostasis (222, 223, 248). The periovulatory increase in TIMPs may coordinate the
actions of MMPs, limiting the location and extent of ECM remodeling to the follicle apex
during the ovulatory process. It is also possible that increased TIMP expression and
activity is necessary for ovulatory processes involving cellular proliferation,
differentiation, or steroidogenesis (225).
Additional information about the role of MMP/TIMP system in the reproductive
tract was obtained from knockout and transgenic mice. These genetically modified
animals did not show major alterations in the reproductive function. Deletion of MMP-9
or TIMP-1 was not associated with an obvious reproductive phenotype in the initial
description of these mice (249, 250), but subsequent analysis has revealed changes in the
reproductive axis (251-254). In mice lacking MMP-9, the individual litters were smaller,
and the percentage of infertile breeding pairs was increased (253). Similarly, TIMP-1null females achieved pregnancy at a lower rate than wild-type mice and had significantly
fewer pups per litter (254). The confounding factor in understanding MMP action in
ovarian and uterine physiology is that removal of one MMP or TIMP often results in
compensation by other members of the MMP family. For example, deletion of MMP-7
results in a 10-12-fold increase in MMP-3 and MMP-10 during uterine involution (255).
Taken together, studies using genetic modification of the MMP system suggest that
compensatory expression of MMP may prevent MMP-specific loss of fertility in
experimental animal models.
The regulation of the MMP system is extremely complex. Signals that regulate
one MMP may differentially regulate other MMPs; signals that upregulate a certain MMP
in one setting may have no effect or even an opposite effect depending on the absence or
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presence of other signals or hormones. It is established that members of the MMP system
that increase during the periovulatory period do so through cascade of events initiated by
LH. The expression of mRNAs for MMP-1, MMP-9, and TIMP-1 increased in monkey
granulosa cells in response to LH treatment in vitro similar to the effects of an ovulatory
dose of gonadotropin in vivo (256). Blocking the endogenous surge of LH with Nembutal
or phenobarbital inhibited the increase in MMP-13 mRNA as well as collagenase activity
(198, 208, 225). Recent and current investigations have begun to examine signal cascade
pathways mediated by LH, such as progesterone, PGs, and cytokines as well as their role
in regulating the periovulatory increase in the MMP system.
The pivotal role of progesterone in follicle rupture is supported by studies in
which ovulation is compromised when progesterone synthesis is inhibited, progesterone
action is blocked by treatment with the progesterone antagonist RU486, or progesterone
receptors expression is lacking (199, 257-259). A role for progesterone in regulating the
MMP system during the ovulatory process is apparent from reports that showed
progesterone stimulated an increase in collagenase-like activity in ovine and hen
follicular tissue; inhibition of progesterone synthesis or blocking progesterone action with
RU486 decreased MMP activity in the rat and ewe (199, 260, 261). In the primate,
treatment with the 3|3-hydrosteroid dehydrogenase inhibitor trilostane decreased the
mRNA expression of MMP-1, MMP-9, MMP-7, TIMP-1, and TIMP-2 (237).
Administration of exogenous progesterone to trilostane-treated macaques restored
expression of MMP-1 and TIMP-1 to control levels.
Additional potential LH-stimulated regulators of the MMPs and TIMPs are PGs.
Inhibition of PG synthesis blocked the periovulatory increase in mRNA for MMP-1 and
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MMP-13 as well as collagenase activity without affecting the gelatinases (234, 260, 262).
In the ewe, inhibition of the preovulatory increase in PGs by administration of
indomethacin suppressed the periovulatory rise in collagenase activity; this suppression
of collagenolytic activity could be restored with exogenous PGE2 or PGF2a (260). For
the TIMPs, blockage of PG production did not affect the mRNA expression patterns for
TIMP-1, TIMP-2, and TIMP-3 in intact rat ovaries, nor did indomethacin administration
affect production of MMP inhibitor activity in conditioned medium of rat granulosa cells
(225, 263). Apparently, in rats, hCG regulation of TIMPs is PG independent.
The above-described studies indicate that the MMP/TIMP system is indeed
involved in proteolysis that occurs in periovulatory follicle and is regulated by the
ovulatory gonadotropin surge. Gonadotropin acts either directly or via progesterone to
increase MMP collagenolytic activity in the follicles. The role of PGs in the regulation of
MMP/TIMP system is still unclear.

2.4.3 Plasminofien activator/plasmin system
The plasminogen activator/plasmin system is a multi-component system that
contains not only proteolytic enzymes but also regulatory components including
inhibitors, cofactors, cell surface receptors and binding proteins (Figure 7). The proteases
of plasminogen activator system are characterized by their catalytic domain consisting of
histidine, asparagine and serine residues (264).
Two major types of plasminogen activators (PAs) have been identified in
mammals: urokinase-type plasminogen activator (uPA) and tissue-type plasminogen
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tPA and uPA
Plasminogen
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PN-1, a2-antiplasmin
a2-macroglobulin
Extracellular matrix degradation

Figure 7. Components of the plasminogen activator/plasmin
system. PAI-1 = plasminogen activator inhibitor 1, PAI-2 =
plasminogen activator inhibitor 2, tPA = tissue type
plasminogen activator, uPA = urokinase type plasminogen
activator, PN-1 = protease nexin 1.
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activator (tPA). These two enzymes differ in their domain organization as well as the
function of their non-catalytic regions (265). They are the products of distinct genes and
are secreted as single-chain proteins. Whereas single-chain tPA is active, single-chain
uPA is essentially inactive (pro-uPA) (266). Cleavage of pro-uPA by plasmin, kallikrein,
Factor Xlla or cathepsin B yields the disulfide-linked double-chain active enzyme (267).
The activation of the PA/plasmin system is initiated by the release of uPA or tPA from
specific cells in response to signals (268). The two PAs have distinct targeting
determinants in their non-catalytic regions: the "growth factor domain" of uPA directs the
binding of the enzyme to a plasma membrane receptor (269, 270), whereas other
structural domains on tPA (the "finger" region and the "kringles") allow its binding to
fibrin and other components of ECM (271). The uPA receptor (uPAR) is present on the
plasma membrane of monocytes, macrophages, fibroblasts, endothelial cells and
keratinocytes (269, 270, 272). The uPAR binds both uPA and pro-uPA with similar
efficacy. This receptor is comprised of at least one 55 kDa polypeptide chain, which is
inserted in the plasma membrane through a glycerophospholipid anchor (273). Receptor
bound uPA remains functionally active at the cell surface with a half-life of 4-5 hours
(274). Studies have shown that receptor bound uPA can still be inhibited by PAI-1 or
PAI-2 although with less efficacy, but it is protected from serum derived inhibitors like
alpha 2-macroglobulin (274-276). Cell membrane-bound high-affinity receptors for tPA
have not been identified. tPA binds to many proteins, and fibrin is by far the most
efficient binding protein. In the presence of fibrin, tPA-catalyzed plasminogen activation
occurs at least 100-fold more effectively than in its absence (277, 278).
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Plasminogen is the preferred substrate for PAs. It is present in plasma and tissue
extracellular fluids at a concentration of 1-2 uM (279). Plasminogen can associate with
fibrin and other proteins via lysine-binding sites located in the kringles of its noncatalytic portion (280). Plasminogen is a single-chain glycoprotein containing 790 amino
acids with a molecular weight of approximately 92 kDa. Native plasminogen is referred
to as Glu-plasminogen since it has a glutamic acid at its N-terminus. Glu-plasminogen is
cleaved by plasmin at Lys76-Lys-77 to produce Lys-plasminogen (281). Both Glu- and
Lys- plasminogen are activated to plasmin by a single PA-catalyzed cleavage at the
Arg560-Val561 bond, which generates a double-chain protein held by two disulfide
bonds. Plasmin catalysis the hydrolysis of Arg-x and Lys-x bonds in fibrin. In addition,
several other proteins that comprise ECM can be easily degraded by plasmin, including
gelatin, fibrinogen, type IV collagen, fibronectin, laminin, elastin, and proteoglycans
(196, 282).
The most important feature of this system is the amplification of the effect
achieved by the reciprocal activation of pro-PAs and plasminogen on the cell surface.
Both plasmin-catalyzed conversion of pro-PA to active PA and the subsequent active PAcatalyzed conversion of plasminogen to plasmin are each accelerated (283). Due to the
high concentration of plasminogen in plasma and body fluids, relatively low levels of PA
production are effective enough to cause high levels of local plasmin production. At the
same time, cell surface inhibition of PA activity can control the activation of PA/plasmin
system in the microenvironment.
Four arginine-specific serine-protease inhibitors (serpins) are of particular
relevance to the PA/plasmin system (284): plasminogen activator inhibitor 1 (PAI-1),
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plasminogen activator inhibitor 2 (PAI-2), protease nexin 1 (PN-1), and a2-antiplasmin.
Serpins are so called suicide inhibitors that mimic the substrate and trap the enzyme in an
inactive stable 1:1 complex (285). The inhibition involves reactive center cleavage and
insertion of the reactive center loop into the inhibitor molecule, after which the covalently
linked protease becomes translocated from one pole of the inhibitor to the opposite one
(286, 287). The preferred target enzyme(s) of different serpins, as determined by the
kinetic constants of complex formation, are different.
PAI-1 is the major PAI in plasma. It has high affinity for tPA, both single-chain
and double-chain, as well as for uPA. PAI-1 is a -54 kDa glycoprotein (288) that has two
mRNAs (2.4 and 3.2 kb), which are thought to be different due to alternative
polyadenylation sites. PAI-1 can exist in its native inhibitory form, in an inactive latent
form, in complexes with proteases, and in a cleaved substrate form (289, 290). In
addition, PAI-1 can form complexes with vitronectin while simultaneously retaining its
activity (291, 292). PAI-1 forms complexes both with single-chain and double-chain-tPA
and with double-chain uPA (288). However, PAI-1 has also been shown to form a
reversible complex with single-chain uPA (293). Receptor bound active uPA is inhibited
by PAI-1 and PAI-2, which leads to the inhibition of plasminogen activation (275, 294,
295).
Based on the amino acid and gene structure, PAI-2 belongs to the ovalbumin
subgroup of the serpin superfamily (296, 297). Its gene is transcribed to a 2.0 kb mRNA
(296). PAI-2 protein exists in two forms: a nonglycosylated intracellular form and a
glycosylated secreted extracellular form (298). PAI-2 inhibits uPA rapidly but inhibits
tPA very slowly (284).
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PN-1 inhibits uPA, plasmin, and thrombin; its reactivity towards thrombin (but
not towards the other two enzymes) is dramatically enhanced in the presence of heparin
(299). PN-1 is mainly produced by fibroblasts, and after secretion it can either stay
associated with the cell surface or is released from the cell. Two forms of PN-I cDNA
(designated a and P) have been identified (300). These differ only by the insertion of
three nucleotides into the coding sequence which is achieved by utilization of an
alternative splice acceptor site in the PN-1 gene. Both forms have been expressed in
mammalian cells and inhibit both thrombin and uPA. The dual role of PN-I as an
inhibitor of fibrin deposition and removal suggests that it may be designed to blunt the
effect of multiple enzymatic pathways (301).
The serpin inhibitor a2-antiplasmin is the primary inhibitor of plasmin (302). It
forms a complex with plasmin by occupying the plasmin kringle domains, i.e. the lysine
binding sites. It is a fast inhibitor of free plasmin both in circulation and solution. When
plasmin/plasminogen is bound to the cell surface, its lysine binding sites are occupied,
therefore a2-antiplasmin acts more slowly (303).
Another inhibitor of PA/plasmin system is a2-macroglobulin, which is found in
circulation in vast quantities (281, 304). This large glycoprotein can trap proteases and
their inhibitor complexes. a2-Macroglobulin complexes are internalized by means of
low-density lipoprotein-related receptor LRP (305). a2-Macroglobulin binds
plasminogen activators and their inhibitor complexes as well as plasmin. Cell-bound
plasmin is protected from a2-macroglobulin (295).
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2.4.4 PA/plasmin system in ovulation
PAs may play a role in ovulation (306, 307). Plasminogen is present in the
follicular fluid, and plasmin can weaken the follicular wall in vitro. Intra-ovarian
administration of PA/plasmin inhibitors or antisera suppresses ovulation in the rat and
ewe (147, 204, 308). Gonadotropin releasing hormone (GnRH) induced plasmin
generation within the apex of ovine pre-ovulatory follicles and the secretion of PA by the
ovarian surface (308). Furthermore, surgical abrasion of ovarian surface epithelium
abolished the production of PA within the follicles and prevented rupture of follicular
wall.
The hypothesis that PAs are responsible for follicle rupture during ovulation was
reinforced by studies showing that tPA and uPA are present in the rat ovary, and PA
expression and activity were regulated by gonadotropins in a cell-specific and time
coordinated manner (208, 309-314). tPA expression was induced by gonadotropins, with
a distinct pattern of expression in different ovarian compartments. tPA was expressed in
both granulosa and theca interstitial cells in periovulatory follicle (314), and maximum
tPA mRNA levels were measured in granulosa cells just prior to ovulation (312). hCG
injection increased tPA activity in a time-dependent manner as measured by fibrin
overlay, reaching a maximum immediately prior to ovulation and declining thereafter
(315). In contrast, mouse periovulatory granulosa cells produced only uPA, while tPA
mRNA was found in mouse theca interstitial cells (316, 317). Both uPA in granulosa
cells and tPA in theca interstitial cells were dramatically upregulated before ovulation,
providing redundant mechanisms for plasmin formation during ovulation. tPA mRNA
expression in granulosa cells and uPA mRNA expression in both granulosa and theca
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cells increased 12 hours after GnRH injection in bovine follicles (318). In the rhesus
monkey, granulosa cell-derived tPA mRNA was substantially elevated in response to
hCG administration (319). tPA expression and activity reached maximum levels just
before ovulation, indicating that tPA may be important for ovulation to occur in nonhuman primates.
Similar to other proteolytic systems, PAs and their inhibitors are regulated by the
same stimuli. In a recent study, hCG administration increased tPA, uPA, PAI-1 and PN-I
mRNA expression in bovine follicle wall homogenates (320). PN-1, PAI-1 and tPA
mRNA expression decreased near the expected time of ovulation, whereas uPA mRNA
levels remained high. PN-1 concentration in follicular fluid decreased and reached the
lowest level at the time of ovulation, whereas plasmin activity in follicular fluid increased
significantly after hCG. In rats, PAI-1 was secreted in a highly regulated manner, mainly
by theca interstitial cells (315). The highest levels of PAI-1 in the rat ovary were found
about 6 hours before ovulation and mainly in the theca interstitial cells and ovarian
stroma, which encapsulate the follicle (314). In mice, the expression of PAI-1 and PAI-2
was found to be low during the periovulatory period, but expression of PN-I by granulosa
cell was high during the entire periovulatory period (317). In bovine granulosa and theca
cells, PAI-1 mRNA expression increased 12 hours after GnRH administration, whereas
PAI-2 in granulosa cells increased only 24 hours after GnRH injection (318). In rhesus
monkey follicular fluid, PAI-1 protein measured by Western blot analysis and PAI-1
activity measured by reverse fibrin overlay reached maximum levels 24 hours after hCG
administration (319). It is probable that PA inhibitors act in a manner similar to that of
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TIMPs to coordinate the actions of PAs to achieve maximum proteolytic activity limited
to the follicular apex.
The above-described studies suggest that the expression and function of PAs and
their inhibitors are regulated by the ovulatory gonadotropin surge. However, it remains
unclear whether in periovulatory follicle gonadotropin acts directly to regulate proteolysis
or via mediators. There is conflicting data about the involvement of PGs in regulation of
PA/plasmin system and plasminogen dependent proteolysis in periovulatory follicles. The
dose of indomethacin that completely blocked ovulation in rats had no effect on either the
magnitude or the time-course of PA activity after intra-peritoneal co-administration with
hCG (321). In cultured rat granulosa cells, PGE2 induced and indomethacin inhibited LH
stimulated production of tPA (322). Moreover, after 24 hours of treatment, PGE2 alone
stimulated PA activity in mural and cumulus granulosa cells in vitro. When administered
before or 3.5 hours after LH administration, the progesterone receptor selective
antagonist Org 31710 significantly suppressed ovulation in perfused rat ovary (323). Org
31710 treatment also decreased the levels of PGE2, PGF2a, and PA activity.
Intrafollicular administration of indomethacin significantly decreased tPA, PAI-1 and
PAI-2 mRNA abundance in bovine periovulatory granulosa cells as well as uPA and
PAI-1 mRNA abundance in theca cells (318). In the same study, tPA activity in the
follicle apex was significantly decreased in response to indomethacin treatment. In
conclusion, while the involvement of PGs in regulation of PAs and their inhibitors in rat
periovulatory follicle is still unclear, there is no data about the role of PGs in
gonadotropin induced plasmin dependent proteolysis in primates.
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The physiological role of tPA, uPA, PAI-1 and plasmin in ovulation were further
assessed by extensive studies on protease deficient mice (324-326). Ovulation efficiency
(mean number of ova per mouse) was determined during gonadotropin-induced ovulation
in young immature mice as well as in adult cycling mice during estrous cycle (325).
Plasminogen deficient mice had decreased ovulation rates. Ovulation efficiency was
normal in mice lacking expression of either tPA, uPA, or PAI-1. However, in tPA/uPA
double knockout mice there was 25% reduction in ovulation efficiency. PN-1 deficient
mice showed decreased male fertility but there were no changes in female reproductive
function (327). As mentioned above, the long-term inactivation of a single protease gene
from the blastocyst stage may induce compensatory mechanisms within the protease
family.
Taken together, these studies suggest that controlled and directed proteolytic
activity generated by PAs and modulated by their inhibitors is involved in the
mechanisms which lead to rupture of selected follicles during ovulation. However, there
are significant interspecies differences regarding the type of PAs and their inhibitors
which are involved in ovulation. Although the ovulatory gonadotropin surge appears to
regulate proteolytic activity in the periovulatory follicle, it is not clear whether the
temporal and spatial restriction of proteolysis is achieved by engaging mediators like PGs
and progesterone. Extremely little is known about PA/plasmin system expression and
regulation in human periovulatory follicle, which makes very relevant the data obtained
from non-human primates.
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2.4.5 ADAMTSs family of metalloproteases and cathepsin L in ovulation
The ADAMTSs are a recently discovered gene family of secreted-type proteases
(328-330). Currently, the ADAMTS family consists of 19 members revealed from the
complete sequence of the human genome (331).
ADAMTSs exert proteolytic activity and biological functions in different tissues
such as skin and cartilage (332-334). ADAMTS-1 has been shown to have antiangiogenic
activity (335). ADAMTS-1-/- mice have considerably reduced size and weight (about
70% of the wild-type or heterozygos animals), obstructive fibrosis in the kidneys,
disrupted capillary network in adrenals and impaired female fertility (336). It is believed
that ADAMTSs may be instrumental for expansion of cumulus-oocyte complex (COC).
COC expansion is a complex process that requires cumulus mucification as well as
extensive reorganization of ECM, with both formation and degradation of its components
(337).
ADAMTS-1, along with ADAMTS-4, -5, -8, and -14, comprises a functional
group of proteases with activities against chondroitin sulfate proteoglycans including
aggrecan, versican, and brevican (334, 338, 339). Versican, one of the preferred
substrates of ADAMTS' activity, is highly inducible by LH in periovulatory follicles
(340). In mice, COCs collected from oviducts contained cleavage product of versican
(341). These data indicate that versican degradation possibly by ADAMTS may be one of
the events that promotes detachment of COCs. In the ovary, ADAMTS-1 was selectively
induced by an ovulatory dose of LH or hCG (220, 235). This induction was clearly
progesterone and progesterone receptor dependent (219, 220). These studies suggested
that ADAMTS-1 has a critical downstream role in mediating the progesterone receptor-
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regulated ovarian activity that culminates in the rupture of follicles. Subfertility in
ADAMTS-1 null female mice due to the impaired ability to ovulate further supports a
key role for ADAMTS-1 in ovulation (336, 342).
Cathepsin L is another LH and progesterone receptor-regulated gene in the ovary
that was identified by cDNA array technology (219). Cathepsin L is a member of the
papain family of enzymes. It is commonly a lysosomal protease, but it is also secreted
from certain endocrine cells, such as Sertoli cells of the testis and placental trophoblasts
and from certain tumors (343). The function of cathepsin L in the ovary appears to be
complex. This enzyme is expressed in granulosa cells of follicles at several different
stages of development in response to both FSH and LH (219). In addition, its expression
in ovulatory follicles is impaired in progesterone receptor null mice. It is possible that
cathepsin L may be a mediator of insulin-like growth factor binding protein's (IGFBP)
clearance in the ovarian follicles, or like cathepsin G, it may activate protease-activated
G-protein coupled receptors on granulosa cells (344, 345). The role of cathepsin L in
ovulation is yet unclear.

The purpose of the study presented in this dissertation is to elucidate the
mechanisms by which ovulatory gonadotropin surge regulates the proteolytic
activity in periovulatory follicles. ECM degradation initiated by proteolytic enzymes
is a vital part of successful ovulation. Although there is ample data to indicate a role
for the PA/plasmin proteolytic system in ovulation, very little is known about the
expression and regulation of these proteolytic enzymes and their inhibitors in the
primate ovary. The importance of PGs in follicle rupture is largely accepted, but
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there is no conclusive evidence linking PGs to proteolysis in ovulation. This study
addresses the role of PGE2 in the regulation of the PA/plasmin system in the
primate periovulatory follicle in vivo and in vitro. In addition, one goal of the
present investigation is to identify specific EP receptors through which PGE2 acts to
mediate gonadotropin-induced proteolysis. These data will provide information that
can be used both to induce and prevent ovulation as needed. The results will support
further studies of receptor-selective agonists and antagonists for the treatment of
infertility as well as the development of novel contraceptives.
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SECTION 3
SPECIFIC AIMS
Specific Aim #1
There are 4 known PGE2 receptors: EP1, EP2, EP3 and EP4. All 4 are G-protein
coupled receptors. Different tissues express different subsets of EP receptors.
Regulation of these receptors is tissue specific.
Aims: Determine 1) which EP receptors are expressed in peri ovulatory granulosa cells
and 2) if EP receptor expression in the ovulatory follicle is gonadotropin regulated.
Hypothesis: One or more EP receptors are expressed in periovulatory granulosa cells.
The ovulatory gonadotropin surge increases EP receptor expression to peak towards the
end of periovulatory period when PGE2 levels are elevated.
Experiments: In Experiment #1, the expression of all 4 EP receptor mRNAs was
measured by real-time RT PCR in granulosa cells collected before (0 hour) and 12, 24,
and 36 hours after administration of an ovulatory dose of hCG. The changes in mRNA
levels of EP receptors showed whether the ovulatory gonadotropin regulates EP receptor
expression on the level of gene transcription.
Experiment #2 examined the protein expression of EP receptor proteins by
immunofluorescence on the frozen tissue sections of ovaries obtained 0, 12, 24, and 36
hours after hCG administration and on paraffin sections of the ovaries obtained on days
0, 1, and 2 after LH surge of the natural cycle. The experiment showed the expression of
EP receptor proteins during the periovulatory period in different compartments of the
ovarian wall (mural granulosa cells and ovarian stroma).
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Experiment #3 examined EP receptor protein expression in granulosa cells by Western
blot analysis in order to quantify the changes in EP receptor protein levels during the
periovulatory period. These experiments determined whether EP receptor protein
increased after gonadotropin administration to reach peak levels towards the end of the
periovulatory period.
Specific Aim #2
EP receptors are coupled with different G proteins and activate different second
messengers. Activation of functional EP1 receptors results in an increased [Ca2+]i.
EP2 and EP4 are coupled to Gas to activate adenylyl cyclase and increase cAMP.
EP3 receptor activation can either increase or decrease cAMP levels or increase
[Ca2+]i, depending on the specific G protein (Gas, Gai, or Gaq respectively)
coupled to the intracellular portion of this receptor.
Aims: Determine 1) which EP receptors are functional and 2) if EP receptor function
changes during the periovulatory period.
Hypothesis: One or more EP receptors are functional and can activate second messengers
in response to PGE2 or receptor selective agonists. The responsiveness of functional EP
receptors is modulated by an ovulatory dose of gonadotropin.
Experiments: In Experiment #1, cAMP levels were measured in granulosa cells obtained
24 and 36 hours after hCG administration. The choice of two time points (24 and 36
hours after hCG) was based on the observation that in the non-human primate, PGE2
levels measured in follicular fluid start to increase 24 hours after hCG administration and
reach the maximum level 36 hours after hCG (79, 99). Granulosa cells were cultured for
16 hours with PGE2 or EP receptor selective agonists or antagonists. The levels of cAMP
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were measured in harvested media by ELISA. The increase of cAMP in response to
PGE2 confirmed the functionality of EP receptors that are linked to adenylyl cyclase. The
EP selective agonists and antagonists identified the specific EP receptors that modulate
cAMP levels. The change between 24 and 36 hours after hCG in the ability of EP
receptor agonists to stimulate cAMP production confirmed that the function of these
receptors is regulated by hCG.
Experiment #2 tested the function of EP1 by measuring [Ca2+]i in granulosa cells
obtained 24 and 36 hours after hCG administration. The cells loaded with a dye that
fluoresces when bound to Ca2+ were treated with PGE2 or PGE2+EP1 receptor
antagonist. PGE2 was used as an EP1 ligand, and an antagonist which blocks PGE2
activity at EP1 receptors was used to differentiate between EP1 or EP3 induced
responses. Confocal images were taken before and after treatments, and these images
were analyzed using Metamorph software to quantify [Ca2+]i. Increased [Ca2+]i after
PGE2 treatment that can be attenuated or abolished by the EP1 receptor antagonist
indicated EP1 receptor activation of the signaling pathway.
Specific Aim #3
In different species, the members of PA/plasmin system (tPA, uPA, and their
inhibitor PAI-1) are involved in proteolytic degradation of the ovarian ECM. The
activity of PA system was shown to increase just before expected time of ovulation,
when the highest levels of PGE2 were measured in follicular fluid.
Aims; Determine 1) which members of PA/plasmin system are expressed in
periovulatory granulosa cells and 2) whether the expression of the enzymes and the
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proteolytic activity of PA system components are regulated by the ovulatory
gonadotropin surge and PGs.
Hypothesis: tPA, uPA, and PAI-1 are expressed in peri ovulatory granulosa cells. Their
expression and proteolytic activity are regulated by gonadotropin. In the late
periovulatory period, gonadotropin regulation of PA system is mediated via PGs.
Experiments: In Experiment #1, mRNA levels of tPA, uPA, and PAI-1 were measured by
real time RT-PCR in granulosa cells obtained 0, 12, 24, and 36 hours after hCG
administration. The changes in mRNA levels during the periovulatory period determined
whether ovulatory gonadotropin regulates the expression of PAs and their inhibitor. To
determine if PGs regulate components of the PA system, mRNA levels of tPA, uPA, and
PAI-1 were measured in granulosa cells that were obtained 36 hours after hCG
administration from the animals treated with the PG synthesis inhibitor celecoxib.
In Experiment #2, tPA, uPA, and PAI-1 proteins were detected by immunofluorescence
on frozen sections from the ovaries that were obtained 0, 12, 24, and 36 hours after hCG
administration. In addition, the expression of these proteins was studied in the ovaries of
animals that received PG synthesis inhibitor treatment during the periovulatory period.
Experiment #3 quantified tPA and PAI-1 in monkey follicular fluid. ELISA kits were
used to measure PAs and their inhibitor in follicular fluids obtained 0, 12, 24, and 36
hours after hCG administration. The changes in secreted protein levels confirmed that
ovulatory gonadotropin regulates protein levels of tPA and its inhibitor PAI-1.
Experiment #4 detected plasminogen-dependent proteolysis on the frozen ovarian
sections by in situ zymography. Proteolytic activity of the PA system was studied in
ovaries obtained 0, 12, 24, and 36 hours after hCG administration. Additional ovaries
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were obtained 36 hours after hCG administration from the animals that received the PG
synthesis inhibitor celecoxib treatment during the periovulatory period. The results of the
experiment elucidated whether PA activity is gonadotropin and PG regulated.
Specific Aim #4
PGE2 is the bioactive PG known to be important for follicle rupture during
ovulation. IntrafoIIicular PGE2 levels as well as the expression and function of
multiple EP receptors increase in the late periovulatory period when proteolytic
enzymes like PAs cause the degradation of follicle wall.
Aims: Determine whether PGE2 is the PG that regulates the components of the PA
system. If PGE2 is involved in the regulation of PA system, then determine which EP
receptors transduce PGE2 effects.
Hypothesis: The induction of PA proteolytic activity by the ovulatory gonadotropin surge
is mediated by PGE2 in the late periovulatory period. The expression of tPA and PAI-1 is
differentially regulated by PGE2 acting through specific EP receptors.
Experiments: This experiment detected tPA and PAI-1 proteins in cultured granulosa
cells. Cells were collected before hCG administration and cultured with an ovulatory
dose of hCG and a PG synthesis inhibitor to inhibit endogenous PGE2 synthesis. After 24
hours in vitro, the cells received PGE2 treatment. Increased protein expression with
PGE2 treatment confirmed that hCG regulation of tPA and PAI-1 was mediated by
PGE2. To identify EP receptors through which PGE2 acts to regulate tPA and PAI-1,
additional granulosa cells received treatment with EP receptor selective agonists.
Changes in the expression of tPA and PAI-1 proteins in EP receptor selective agonist
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treated cells identified the specific EP receptors involved in the regulation of these
proteins.

69

SECTION 4
STUDIES FOR SPECIFIC AIMS #1 AND #2
4.1 Materials and Methods for Specific Aims #1 and #2

Animals
Granulosa cells and whole ovaries were obtained from adult female cynomolgus
macaques at Eastern Virginia Medical School (Norfolk, VA). All animal protocols and
experiments were approved by the Eastern Virginia Medical School Animal Care and
Use Committee and were conducted in accordance with the National Institutes of Health
Guide for the Care and Use of Laboratory Animals. Monkeys were maintained in
temperature-controlled rooms on a 12-hour light, 12-hour dark cycle. Animals were fed
commercial monkey chow and had water available at all times. Adult females with
regular menstrual cycles were checked daily for menstruation; the first day of
menstruation was designated day 1 of menstrual cycle. Blood samples were obtained
under ketamine chemical restraint (5-10 mg/kg body weight) by femoral venipuncture,
and serum was stored at -20°C. Aseptic surgeries were performed in a dedicated surgical
suite under isofluorane anesthesia and involved midline laparotomy or laparoscopy.
A controlled ovarian stimulation model developed for the collection of multiple oocytes
for in vitro fertilization was used to obtain monkey granulosa cells (257, 346). Beginning
within 3 days of initiation of menstruation, recombinant human FSH (90 IU daily, Serono
Reproductive Biology Institute, Rockland, MA and Organon, Inc, a part of Schering
Plough, Inc., Roseland, NJ) was administered for 6-8 days, followed by daily
administration of 90 IU of recombinant human FSH plus 60 IU r-hLH (Serono) for 2
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days to stimulate the growth of multiple follicles. The GnRH antagonist Antide (0.5
mg/kg body weight; Serono) was also administered daily to prevent an endogenous
ovulatory LH surge. Adequate follicular development was monitored by serum estradiol
levels and ultrasonography (347, 348). Follicular aspiration was performed by
laparotomy and laparoscopy before (0 h) or 12, 24, and 36 hours after administration of
] 000 IU r-hCG (Serono). In spontaneous menstrual cycles, follicle rupture in monkeys
occurs approximately 40 hours after the ovulatory gonadotropin surge (349), so these
times span the periovulatory interval. To obtain granulosa cells, each follicle was pierced
with a 22-gauge needle, and the aspirated contents of all follicles larger than 4 mm in
diameter were pooled. Whole ovaries were also obtained from monkeys undergoing
ovarian stimulation. Additional whole ovaries were collected from monkeys experiencing
spontaneous menstrual cycles around the expected time of the endogenous LH surge
(349). These ovaries were obtained before, during, 1 day after, and 2 days after the LH
surge (n = 2-3/day) as defined by serum estradiol, LH and progesterone concentrations
before and at the time of organ removal (350). Monkey kidney tissue was obtained at
necropsy.

Tissue preparation
Monkey granulosa cells and oocytes were pelleted from follicular aspirates by
centrifugation. Oocytes were mechanically removed, and a granulosa cell-enriched
population of the remaining cells was obtained by Percoll gradient centrifugation (350).
Viability of granulosa cell-enriched preparations averaged 76.2% as assessed by trypan
blue exclusion. Cells were either used immediately for cell culture or were frozen in
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liquid nitrogen and stored at -80°C for preparation of total RNA or cell lysates. Whole
stimulated ovaries were bisected, maintaining at least two periovulatory follicles greater
than 4 mm in diameter on each piece. The pieces were covered with O.C.T. Compound
(Sakura, Tokyo, Japan), frozen in liquid propane and stored at -80°C. Natural cycle
ovaries were fixed in 4% paraformaldehyde and embedded in paraffin. Monkey kidney
tissue was either frozen in liquid propane and stored at -80°C or was fixed in 4%
paraformaldehyde and embedded in paraffin.

Real-Time RT-PCR
EP receptor mRNA levels were analyzed by real-time RT-PCR using a Roche
LightCycler (Roche Diagnostics, Indianapolis, IN). Total RNA was obtained from
granulosa cells using Trizol reagent (Invitrogen, Rockville, MD), treated with DNase,
and reverse transcribed as previously described (51). PCR was performed using the
FastStart DNA Master SYBR Green I kit (Roche) following manufacturer's instructions
and using 0.5 uM primers and 4 mM MgC^. Primers were designed using LightCycler
Probe Design software (Roche) based on the human or monkey sequences (Table 1) and
span an intron whenever possible to prevent undetected amplification of genomic DNA.
PCR products were sequenced (Microchemical Core Facility, San Diego State University,
CA) to confirm amplicon identity. At least 5 log dilutions of the sequenced PCR product
were included in each assay and used to generate a standard curve. When amplification
was not detected in two EP1 samples, the lower limit of detection of the assay (15
copies/40 ng of cDNA) was applied for statistical analysis. For each sample, the content
of each EP receptor and p-actin mRNA was determined in independent assays. No
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Table 1. Reaction conditions for Real Time RT-PCR for EP1, EP2, EP3, and EP4
Receptor mRNA
Primer sequences (5'-3')

EP1
EP2
EP3
EP4

Pactin

up: GCTTGTCGGTATCATGG
dn: GGAAGCGAAGCAGTTG
up: GAACAATCGGCTGCAC
dn:GGACTTCCTAGAGACTACAT
up: CGGGACTAGCTCTTCG
dn: TTATCAGGAGCGGAGAC
up: TCTGTGAACCCCATCC
dn: CTGATATTCGCAAAGTCC
up:ATCCGCAAAGACCTGT
dn:GTCCGCTAGAAGCAT

Amplified
cDNA
(bp)

Published
monkey and
human
sequences

203

AJ884597

% identity
between
monkey
and
published
human
and
monkey
sequences
99.4

Monkey
amplified
fragment
accession
number

DQ356253

202

NM000956

94.0

DQ356252

251

NM000957

98.8

DQ091281

358

NM_000958

99.0

DQ334856

270

NM001101

97.4

AY765990
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amplification was observed when monkey cDNA was omitted. All data were expressed
as the ratio of EP mRNA to P-actin mRNA for each sample. Intra- and inter-assay
coefficients of variation were less than 10%.

Immunofluorescent detection of EP receptors
Frozen ovarian and kidney tissues were sectioned at 10 um and fixed with
buffered 10% formalin. After antigen retrieval using Antigen Retrieval Citra treatment
(BioGenex Labs, San Ramon, CA), the sections were blocked with 5% non-immune goat
serum (Vector Laboratories, Burlingame, CA) in phosphate-buffered saline containing
0.1% Triton (PBS-Triton). Sections were then incubated overnight with either primary
antibody generated against one of the EP receptors [EP1 (1 ng/ml). EP2 (5 u.g/ml), EP3
(2 p.g/ml), EP4 (3 u,g/ml)] or primary antibody+blocking peptide (Cayman Chemicals,
Ann Arbor, MI), followed by incubation with a Alexa Fluor 488 conjugated anti-rabbit
secondary antibody (1:500; Molecular Probes, Eugene, OR). After incubation with 1%
Sudan Black in 70% methanol, the slides were coverslipped using Vectashield medium
(Vector Labs). All images were obtained using an Olympus BX41 fluorescent
microscope fitted with a DP70 digital camera and associated software (Melville, NY).
Paraffin embedded ovarian and kidney tissue sections (5 um) were deparaffinized,
exposed to antigen retrieval as described above, and incubated with Image-iT signal
enhancer (Molecular Probes). After exposure to 5 % n o n - i m m u n e serum block in P B S -

Triton, sections were incubated with streptavidin and biotin (Vector Labs). After the
overnight incubation with either primary antibodies against each EP receptor [EP1 (3
p,g/ml), EP2 (1 ug/ml), EP3 (3 p-g/ml), EP4 (3 |J.g/ml)] or with primary
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antibody+blocking peptide followed by biotinylated anti-rabbit secondary antibodies
(1:200, Vector Labs), the sections were treated with Streptavidin-Alexa Fluor 488
(Molecular Probes), then with 1% Sudan Black, coverslipped and photographed as
described above.

Western blotting
Western blotting was performed on enriched granulosa cell populations obtained
from monkey and human follicular aspirates. Human luteinizing granulosa cells were
obtained after oocyte removal from follicular aspirates from patients experiencing
ovarian stimulation at The Jones Institute for Reproductive Medicine, EVMS. This use
of discarded human granulosa cells does not constitute human subjects research as
determined by the EVMS Institutional Review Board. No information is obtained
regarding an individual patient's diagnosis or treatment protocol. However, most patients
receive hCG 34-36 hours prior to follicle aspiration, so these human cells are very similar
to monkey granulosa cells obtained 36 hours after hCG administration. Human granulosa
cells were enriched by Percoll gradient centrifugation as described above for monkey
granulosa cells. Denatured granulosa cell lysates were loaded onto 4-20% gradient
polyacrylamide Tris-HCl gels (Bio-Rad, Hercules, CA). Four dilutions of granulosa cell
lysates were loaded onto the gel to show that the samples were in the linear range of
detection. Proteins were transferred to polyvinylidene fluoride m e m b r a n e s (Imobilon,

Millipore, Billerica, MA), and western blotting was carried out with rabbit polyclonal
primary antibodies against EP1 (6 i^g/ml), EP2 (5 jig/ml), and EP3 (4 pg/ml) and an antirabbit immunoglobulin G (IgG)-horseradish peroxidase conjugated secondary antibody
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(1:10,000; Amersham, Piscataway, NJ, USA). Bands were detected by enhanced
chemiluminescence (ECL; Amersham). Blots were then stripped of primary and
secondary antibodies following instructions provided by the membrane manufacturer, and
western blotting was performed on the stripped membranes using a mouse anti-tubulin
primary antibody (1:1000; Sigma) and anti-mouse IgG-horseradish peroxidase conjugate
secondary antibody (1:20,000; Amersham). The molecular size of bands representing
each EP receptor and tubulin were determined by comparison to prestained standards
(Bio-Rad). Films were scanned and analyzed densitometrically using SigmaGel software
(Jandel Scientific, San Rafael, CA). EP content of each granulosa cell sample is
expressed as EP protein/tubulin ratio.

Granulosa cell culture
Monkey granulosa cells were plated on 48 well or 96 well tissue culture plates or
Lab-Tek chamber slides (Nalge Nunc International, Rochester, NY) coated with
fibronectin (Sigma, St. Louis, MO, USA) at a concentration of 10,000 cells/100 ul
medium. The cells were cultured in serum free DMEM-Ham's F12 medium containing
insulin (2 jag/ml), transferrin (5 ug/ml), selenium (0.25 nM), aprotinin (10 (ag/ml), and
human low-density lipoprotein (25 |J.g/ml) (351).

cAMP measurements
Cells were cultured with PGE2 (luM), PGE2+the EP1/EP2 antagonist AH6809
(10 uM), the EP2 agonist butaprost (10 uM), the EP3 agonist sulprostone (luM)
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(Cayman), or no treatment (control). Media were stored at -20°C until acetylated prior to
assay for cAMP by enzyme immunoassay (Cayman), which was performed and analyzed
following kit instructions. The lower limit of detection for the assay was used for
statistical analysis when the calculated cAMP concentration of one control sample was
below the level of detection. All cAMP levels were normalized to the protein content of
cultured cells as determined by the bicinchoninic acid method (Sigma). Preliminary
studies showed a dose dependent increase in cAMP production in response to PGE2
(Appendix 1), and a linear increase in cAMP levels measured between 4-24 hours in the
media of cultured granulosa cells treated with PGE2 (1 uM, Appendix 2). For studies
presented here, media for cAMP assay was collected 16 hours after agonist/antagonist
addition. For each animal, data are presented as a ratio of the EP agonist-stimulated
cAMP level to the cAMP level in the untreated (control) cultures.

TCa2+li measurements
For [Ca2+]i (intracellular Ca2+ concentration) measurements, granulosa cells
were incubated for 30 minutes in Hanks' balanced salt solution containing 1.8 mM CaCb
and the fluorescent dye Fluo 3AM (Molecular Probes) at 1:1000 dilution. The basal
fluorescent emission of cells was determined before treatment (0 seconds (sec)).
Granulosa cells were then stimulated with PGE2 (1 uM) and imaged every 20 seconds for
2 minutes. Finally, cells were exposed to the calcium ionophore calcimycin (10 uM,
Calbiochem, San Diego, CA); only cells with increased fluorescence after calcimycin
treatment were included in quantitative analyses. A second culture of cells received 60
second pretreatment with AH6809 (10 uM), after which PGE2 was added, and the cells
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were imaged as described above. Images of cells were obtained using a confocal
microscope (Zeiss LSM - 510, Carl Zeiss Inc, Thornwood, NY) at absorption and
emission wavelengths of 506 nm and 526 nm, respectively. For each treatment, ten
calcimycin-responsive cells were analyzed for fluorescence using MetaMorph software
(Molecular Devices, Sunnyvale, CA), and [Ca2+]i was calculated using the following
formula: [Ca2+]i=Kd (Ca2+) X (F-Fmin)/Fmax-F, where Kd (Ca2+) = 325 nM, Fmin is
the fluorescence measured in the absence of Fluo 3AM in the medium, F is the
fluorescence of the cells in the medium containing Fluo 3 AM, and Fmax is the
fluorescence after addition of calcimycin (352, 353). For each animal, [Ca2+]i of cells
before treatment was set equal to 1.0, and [Ca2+]i in the same cells after treatment was
expressed relative to pretreatment levels.

Data analysis
All data were assessed for heterogeneity of variance and log transformed when
Bartlett's test yielded a significance of <0.05. Data presented in Fig. 7 (Panels C and D),
Fig. 10 and Fig. 11 were log transformed before further analysis. In all figures,
untransformed data are presented. PCR and Western blot data were assessed by ANOVA.
cAMP and [Ca2+]i data were assessed by ANOVA with 1 repeated measure. In all cases,
post hoc analysis was performed using Duncan's Multiple-Range test. In addition, EP2
protein levels at 0 hour and 36 hours were compared by 2-tail t-test. Statistical analyses
were performed using StatPak v4.12 software (Northwest Analytical, Portland, OR). Data
are presented as mean+standard error of the mean (SEM), and significance was assumed
atp value<0.05.
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4.2 Results for Specific Aims #1 and #2

EP mRNA expression by monkey granulosa cells
Monkey granulosa cell expression of EP receptor mRNA was examined before
and after administration of an ovulatory dose of hCG at times which span the 40-hour
long periovulatory interval in primates. EP1, EP2, EP3, and EP4 mRNA was detected in
granulosa cells before (0 hour) hCG administration (Figure 8). Levels of EP1, EP2, and
EP4 mRNA did not change in response to hCG exposure. In contrast, EP3 mRNA levels
were low before (0 hour), elevated at 12 hours, and remained elevated 24-36 hours after
hCG administration.

EP receptor proteins in monkey granulosa cells
EP1 receptors were not detected in granulosa cells of monkey periovulatory
follicles by immunofluorescence at 0 and 12 after hCG (Figure 9A and data not shown).
There was sporadic EP1 fluorescence in granulosa cells of ovaries obtained 24 hours after
hCG, but the intensity of fluorescence for EP1 increased notably in granulosa cells of
ovaries obtained 36 hours after hCG (Figure 9B, C). EP1 immunofluorescence was also
present in the monkey kidney (Figure 9D), confirming previous reports (124, 155) and
serving as a positive control. EP1 was not detected when the primary antibody was
omitted (data not shown) or preincubated with the blocking peptide (Figure 9C, D insets).
The EP2 protein was detectable by immunofluorescence in granulosa cells of
periovulatory follicles obtained 0, 12. 24, and 36 hours after hCG (Figure 9E, F, G and
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Figure 8. EP receptor mRNA expression in monkey granulosa
cells. Granulosa cells were obtained from monkeys
experiencing controlled ovarian stimulation before (0 hour) and
12, 24, and 36 hours after hCG administration. mRNA were
determined by real time RT-PCR; all mRNA levels are
expressed relative to P-actin. Data are presented as mean±SEM
(n=4-5 animals/time point). In panel C, groups with different
letters are different by ANOVA and Duncan's Multiple-Range
test, p value<0.05. Modified from Markosyan et al. (376).
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0 hour

24 hour

36 hour

Kidney

Figure 9. Immunofluorescent detection of EP receptors in monkey granulosa
cells. Ovaries were obtained from monkeys experiencing controlled ovarian
stimulation at 0 h (A, E, I, M), 24 h (B, F, J, N), and 36 h (C, G, K, O) after
hCG administration. In each periovulatory follicle shown, the antrum (a) is in
the upper right, granulosa cells (gc) are central, and the ovarian stroma (s) is
in the lower left portion of the image. Immunodetection (bright green) of
EP1 (A, B, C), EP2 (E, F, G), EP3 (I, J, K), and EP4 (M, N, O) in
periovulatory follicles is shown. Immunodetection of EP1 (D), EP2 (H), EP3
(L), and EP4 (P) in monkey kidney served as a positive control. No
fluorescence was observed when the primary antibodies were preabsorbed
with the blocking peptide (C, D, G, H, K, L, O, P insets) or when the primary
antibody was omitted (not shown). Ovarian images shown are representative
of 3-4 animals/time point. For all panels, bar = 50 um. Modified from
Markosyan et al. (376).
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data not shown). EP2 immunofluorescence was not observed in the ovarian stroma.
Monkey kidney tissue exhibited low levels of EP2 protein detection (Figure 9H) as
reported by others (140, 155). As with EP1, EP2 immunofluorescence was absent when
the primary antibody was omitted or preincubated with the blocking peptide (Figure 9G,
H insets and not shown). Western blotting using this EP2 antibody detected a single 52
kDa band in lysates of granulosa cells obtained 0, 24, and 36 hours after hCG (Figure
10A), which was eliminated when the primary antibody was preincubated with the
blocking peptide (Appendix 3). Tubulin was detected as a single band at 50 kDa. While
ANOVA showed a tendency for EP2 levels to increase with hCG exposure (p
value=0.07), EP2 levels increased between 0 hour and 36 hours as determined by t-test (p
value=0.02; Figure IOC).
EP3 was detected by immunofluorescence in granulosa cells of periovulatory
follicles obtained 0, 12, 24, and 36 hours after hCG; EP3 was also observed in the
ovarian stroma (Figure 91, J, K and data not shown). In the kidney, EP3 was detected in
tubules (Figure 9L), previously reported to express this EP receptor (161, 354). EP3
immunofluorescence was eliminated in granulosa cells when the primary antibody was
omitted or preabsorbed with the blocking peptide (Figure 9K, L insets and data not
shown). EP3 protein was detected in granulosa cells by western blotting as multiple
bands, with the strongest band at 65 kDa (Figure 1 OB). All bands were absent when blots
were probed with primary antibody preincubated with the blocking peptide (Appendix 3).
EP3 levels increased in response to hCG, with peak levels measured in granulosa cells
obtained 36 hours after hCG administration (Fig. 9D). EP4 protein was not detected
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Figure 10. EP2 and EP3 proteins in the monkey periovulatory
follicle. Granulosa cells obtained before (0 h), 24 h, and 36 h after
hCG administration were subjected to Western blotting for EP2 (A),
EP3 (B) and tubulin, which was detected as a single band of 50 kDa
in each sample. Protein levels for EP2 (C) and EP3 (D) are expressed
relative to the tubulin content of each sample. Data are expressed as
mean±SEM (n=3-4 animals/time point). In panel D, groups with
different letters are different by ANOVA and Duncan's MultipleRange test, p value <0.05. EP2 protein was different between 0 h and
36 h groups by 2-tailed t-test (p value=0.02). Modified from
Markosyan et al. (376).
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by immunofluorescence in granulosa cells of periovulatory follicles obtained 0,12,24,
and 36 hours after hCG administration; EP4 was, however, consistently detected in the
ovarian stroma (Figure 9M, N, O and data not shown). EP4 protein showed high levels of
expression in kidney glomeruli (Figure 9P) as previously reported (124, 155), which
served as a positive control. EP4 immunofluorescence was not present when the primary
antibody was preabsorbed or omitted (Figure 90, P insets and not shown).
Immunofluorescence on the paraffin sections of monkey ovaries obtained during
natural menstrual cycles showed a similar pattern of EP receptor detection (Appendix 4).
EP1 detection was absent or very low in granulosa cells of follicles obtained before or
immediately after the ovulatory LH surge (Appendix 4A, B), but EP1 was present in
granulosa cells of periovulatory follicles obtained on day 1 (data not shown) and day 2
after the LH surge (Appendix 4C). EP2 and EP3 were detectable in granulosa cells of
periovulatory follicles obtained before and after LH surge (Appendix 4D-F, G-I). EP4
was low/nondetectable in granulosa cells at all times examined (Appendix 4J-I). These
data demonstrate that the expression and localization of EP receptor proteins described
above for stimulated monkey ovaries is consistent with EP localization and gonadotropinregulated expression as seen in ovaries obtained during natural menstrual cycles.
Because EP4 receptors were not consistently detected in granulosa cells of ovaries
obtained after controlled ovarian stimulation or during natural menstrual cycles,
measurement of intracellular second messengers by granulosa cells via EP4 receptor
stimulation was not pursued in the studies described below.
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EP stimulation of granulosa cell cAMP generation
To determine if stimulation of EP2 and EP3 receptors regulates cAMP levels in
granulosa cells via interactions with Gas or Gai, cells were cultured with EP2 and EP3
receptor agonists and antagonists. In granulosa cells obtained 24 hours after hCG, PGE2
increased cAMP levels 5-fold above levels measured in control cells (Figure 11 A). The
ability of PGE2 to elevate media cAMP was abolished by coincubation with the EP1/EP2
antagonist AH6809. The EP2 agonist butaprost increased cAMP to levels intermediate
between PGE2 and PGE2+AH6809. The EP3 agonist sulprostone did not alter granulosa
cell cAMP levels. In the same cells, treatment with butaprost+sulprostone
increased cAMP to levels which were not different from cAMP levels measured after
stimulation with PGE2 (3.38±1.23 and 7.02±2.59 fold above control, respectively, n==3).
The ability of EP agonists and antagonists to alter cAMP accumulation in
granulosa cells obtained 36 hours after hCG was also examined. PGE2 treatment induced
a 8-fold increase in media cAMP, which was eliminated by coincubation with AH6809
(Figure 1 IB). Butaprost stimulated a 4-fold increase in cAMP while sulprostone doubled
cAMP levels when compared to controls. In the same cells, treatment with
butaprost+sulprostone yielded cAMP levels which were not different from PGE2 induced
cAMP levels ((5.64±1.98 and 6.12±1.98 fold above control, respectively, n=3).

EP stimulation of intracellular calcium in granulosa cells
To determine if EP1 stimulation leads to changes in granulosa cell [Ca2+]i,
cellular response to treatment with PGE2 or PGE2+the EP1/EP2 antagonist AH6809 was
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Figure 11. cAMP production by monkey periovulatory granulosa
cells. Granulosa cells were obtained from monkeys experiencing
controlled ovarian stimulation 24 h (A) and 36 h (B) after hCG
administration. The cells were incubated for 16 h with PGE2, PGE2
+AH6809, butaprost, sulprostone or no treatment (control). Media
cAMP was measured by enzyme immunoassay. For each animal, the
cAMP level in control cells was set equal to 1.0, and the cAMP level
in treated cells was expressed relative to the control level. Data are
presented as mean±SEM (n=5-6 animals/time point). Within each
panel, groups with different letters are different by ANOVA and
Duncan's Multiple-Range test, p value<0.05.
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assessed. Granulosa cells obtained 24 hours after hCG administration failed to increase
[Ca2+]i in response to PCrE2 but did respond with increased fluorescence to calcimycin
treatment (Figure 12A, B, C). In granulosa cells obtained 24 hours after hCG
administration, treatment with PGE2 or PGE2+AH6809 did not alter [Ca2+]i when
compared to basal levels (Figure 12G). In granulosa cells collected 36 hours after hCG,
PGE2 treatment doubled [Ca2+]i after 20 seconds (Figure 12D, E). As anticipated, the
increase in [Ca2+]i levels was transient and declined after the initial peak. However, by
120 sec after treatment, [Ca2+]i levels remained elevated above the levels in the same
cells before the treatment. EP1/EP2 antagonist AH6809 abolished the PGE2 induced
increase in [Ca2+]i (Figure 12H).

4.3 Discussion for Specific Aims #1 and #2

The present study is the first to examine the expression and function of all known
EP receptors in primate periovulatory granulosa cells. Much attention has focused on the
identification of PGE2 as the essential ovulatory PG as well as the ability of the ovulatory
gonadotropin surge to increase granulosa cell expression of PG synthesis enzymes,
resulting in peak follicular PGE2 levels just before follicle rupture (51, 79, 83, 85).
However, the data presented in this report suggest that the ovulatory gonadotropin surge
also regulates granulosa cell responsiveness to PGE2 during the periovulatory period.
Exposure to an ovulatory dose of hCG increased granulosa cell expression of EP1, EP2,
and EP3 receptors as well as intracellular signal generation in response to agonist
stimulation of these EP receptors. Taken together, these data support the hypothesis that
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Figure 12. PGE2 regulation of [Ca2+]i in monkey periovulatory
granulosa cells. Granulosa cells were obtained from monkeys
experiencing controlled ovarian stimulation either 24 h (A, B, C) or 36
h (D, E, F) after hCG administration. Cells were imaged before
treatment (0 sec; A, D), 20 sec after PGE2 addition (B. E) and 60 sec
after calcimycin addition (C, F). In panels A-C, arrows indicate 2
representative cells before and after treatment. Similarly, arrows
indicate 2 representative cells in panels D-F. Images are representative
of 4-5 animals/time point. [Ca2+]i levels in PGE2 treated cells (filled
circles) and AH6809+PGE2 treated cells (open circles) relative to basal
[CaH]i level at 0 sec (represented by the horizontal line at intracellular
calcium=l .0) are plotted for the granulosa cells obtained 24 h (G) and
36 h (H) after hCG administration. Data are presented as mean±SEM
(n=4-5/time point). In panel H. groups with different letters are
different by ANOVA and Duncan's Multiple-Range test,
p value<0.05.
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the ovulatory gonadotropin surge regulates EP receptors to achieve peak granulosa cell
responsiveness to PGE2 in the hours just before ovulation. In the present study, mRNA
for EP1, EP2, EP3 and EP4 was detected in granulosa cells of monkey periovulatory
follicles before and after hCG administration. Studies by others have shown that mRNA
for EP1, EP2, and EP4 are expressed in either freshly isolated or long term cultured
human luteinizing granulosa cells (127, 144); EP3 expression in human granulosa cells
has not been reported. EP2, EP3, and EP4 mRNA are present in bovine cumulus
granulosa cells (355, 356). Reports of sub-fertility in EP2 knockout mice (146) focused
attention on EP2 expression and function in rodent granulosa cells (357). However,
recent detection of EP2 and EP4, but not EP1 and EP3, mRNA in mouse granulosa cells
supports the hypothesis that multiple EP receptors mediate the ovulatory effects of PGE2
(143). Clearly, granulosa cell EP expression differs between species. These data,
combined with our detection of mRNA for all EP receptors in primate granulosa cells,
suggest that the ovulatory effects of PGE2 may require multiple EP receptors.
The present study also demonstrated that primate granulosa cells express EP1,
EP2, and EP3 receptor proteins. EP2 and EP3 receptors were both detected in granulosa
cells obtained before hCG administration. In response to administration of an ovulatory
dose of hCG, levels of EP1, EP2, and EP3 receptors increased to peak 36 hours after hCG
administration, just before ovulation. Interestingly, EP4 protein was not detected in
monkey granulosa cells, despite the presence of EP4 mRNA at every time examined.
Granulosa cell EP3 mRNA and protein levels both increased in response to hCG
administration. Although EP3 mRNA levels increased considerably 12 hours after hCG
administration, the increase in EP3 protein expression was measured only 36 hours after
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hCG. Levels of EP1 and EP2 proteins also increased in response to hCG, despite
unchanged levels of their respective mRNAs. To our knowledge, this study represents the
first report of EP receptor proteins in primate granulosa cells. Our data indicate that the
ovulatory gonadotropin surge stimulates granulosa cell EP receptor expression to achieve
maximal EP protein concentrations just before ovulation, when follicular PGE2 levels
reach their peak.
The EP receptors which mediate the ovulatory PGE2 signal in primates have not
been identified. Mice lacking expression of EP2 have decreased ovulation and
fertilization efficiency. In contrast, deficiencies of EP1 and EP3 expression did not
negatively impact reproductive function (145, 146, 358, 359). In the primate
periovulatory follicle, PGE2 begins to accumulate in follicular fluid 24 hours after hCG
administration and reaches peak levels 36 hours after hCG, or just before ovulation (51,
79, 85, 99). Therefore, the EP receptors involved in mediating the ovulatory PGE2
signal should be present on granulosa cells 24-36 hours after hCG administration. The
present study demonstrated that primate granulosa cells have EP1, EP2, and EP3
receptors available to mediate the ovulatory effects of PGE2. Therefore, additional
studies were performed to determine which EP receptors are functional during the
period of elevated PGE2 which precedes primate ovulation.
EP1 couples to Gaq to activate phospholipase C and produce inositol
trisphosphate, which increases [Ca2+]i by release of calcium from intracellular stores
(360). PGE2 treatment increased [Ca2+]i when granulosa cells were obtained 36 hours
after hCG administration in vivo; granulosa cells obtained 24 hours after hCG did not
respond to PGE2 with increased [Ca2+]i. These data are consistent with our detection of
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EP1 protein in granulosa cells 36 h, but not 24 h, after hCG administration. The ability of
PGE2 to increase [Ca2+]i was abolished by the EP1/EP2 receptor antagonist AH6809. It
is unlikely that PGE2 acts via EP2 receptors to increase [Ca2+]i. EP2 receptors couple
exclusively to Gas to increase cAMP (360, 361). While cAMP can increase [Ca2+]i via
cyclic nucleotide gated Ca2+ channels (362), there are no reports of these channels in
granulosa cells. Therefore, the ability of AH6809 to prevent the PGE2-stimulated
increase in [Ca2+]i best supports the hypothesis that PGE2 increases fCa2+]i via EP1
receptors. The presence of functional EP1 receptors only late in the periovulatory
interval suggests that EP1 mediates at least some of the ovulatory effects of PGE2 in
primate granulosa cells.
EP2 couples to Gas and activates adenylyl cyclase to stimulate cAMP production
(360). Both PGE2 and the EP2 agonist butaprost increased cAMP production by
granulosa cells obtained 24 hours and 36 hours after hCG administration in vivo. This
effect of PGE2 was more potent in granulosa cells obtained 36 hours after hCG; these
cells also had the highest levels of EP2 protein. The EP1/EP2 antagonist AH6809
reduced or abolished PGE2-stimulated cAMP production in all granulosa cell cultures
examined. Because EP1 receptors couple exclusively to Gaq, these data support the
conclusion that PGE2 stimulates adenylyl cyclase activity through the EP2 receptor.
However, butaprost did not increase cAMP to the levels measured in PGE2-treated
cultures of granulosa cells obtained 24 hours after hCG. While PGE2 may be more
efficacious than butaprost as a ligand for the monkey EP2 receptors, PGE2 may also act
through EP receptors in addition to EP2 to achieve maximal cAMP production. Taken
together, our data are consistent with studies in human and rat granulosa cells (127, 143)
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and demonstrate that primate periovulatory granulosa cells express functional EP2
receptors. Importantly, this study is the first to demonstrate that granulosa cell response
to EP2 receptor stimulation increases late in the periovulatory period to peak just before
ovulation.
EP3 receptors expressed by monkey granulosa cells couple primarily, if not
exclusively, to Gas. Numerous isoforms of EP3 have been characterized to date (150).
EP3 receptors which couple to God and Gaq have been reported in human cells (363).
Our studies suggest that the EP3 receptor isoforms expressed by primate granulosa cells
couple to Gas. The PCR primers used in this study were designed to detect all 10 known
human EP3 mRNA splice variants, and western blotting consistently identified 3 EP3
isoforms in monkey periovulatory granulosa cells. In granulosa cells obtained 36 hours
after hCG administration, treatment with the EP3 receptor agonist sulprostone increased
cAMP, suggesting that one or more EP3 receptor isoform couples to Gas. Additionally,
sulprostone did not decrease basal or butaprost-stimulated cAMP, so it is unlikely that
EP3 receptors couple to Gai in monkey granulosa cells. Gaq coupled EP3 receptors
which increase [Ca2+]i were also not detected in monkey granulosa cells as the EP1/EP2
antagonist AH6809 completely abolished the PGE2 induced increase in [Ca2+]i.
Therefore, granulosa cells likely respond to the ovulatory gonadotropin surge with an
increase in Gas coupled EP3 receptors, with PGE2 acting in part via EP3 receptors to
increase cAMP production late in the periovulatory interval.
In summary, this study is the first to demonstrate expression and function of three
distinct EP receptors in primate periovulatory granulosa cells. Exposure of granulosa
cells to an ovulatory dose of hCG increased levels of EP1, EP2, and EP3 receptor
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proteins; granulosa cell responsiveness to PGE2 also increased as the expected time of
ovulation drew near. Because each of these three EP receptors may regulate different
intracellular events, PGE2 may utilize multiple pathways to stimulate periovulatory
events in primate granulosa cells. The present data support the hypothesis that the
ovulatory gonadotropin surge increases PGE2 levels within the follicle as well as the
expression and function of EP receptors. Both PGE2 levels and EP receptor
responsiveness peak just before ovulation, ensuring the maximal ovulatory effect of
PGE2.
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SECTION 5
STUDIES FOR SPECIFIC AIMS #3 AND #4
5.1 Materials and Methods for specific Aims #3 and #4

Animals
The animal husbandry, controlled ovarian stimulation and sample collection were
performed as described for specific aims #1 and #2. Follicular aspirates were obtained
before (0 hour) or 12, 24, or 36 hours after administration of 1000 IU r-hCG (Serono). To
inhibit follicular PG production during the periovulatory interval, additional animals were
treated with gonadotropins and Antide as described above; these animals also received
the COX-2 selective inhibitor celecoxib (Celebrex, Pfizer, New York, NY) 32 mg orally
every 12 hours beginning with hCG administration until follicles were aspirated 36 hours
later. This treatment was previously shown to decrease follicular fluid PGE2 to very low
levels (364). Whole ovaries were obtained from monkeys experiencing ovarian
stimulation with or without celecoxib treatment.

Tissue preparation
Granulosa cell-enriched preparation and follicular fluid were obtained from
follicular aspirates as described for specific aims #1 and #2. Granulosa cells were either
used immediately for cell culture or were frozen in liquid nitrogen and stored at -80°C
for preparation of total RNA. Viability of granulosa cell-enriched preparations was
assessed by trypan blue exclusion and averaged 76%. Whole ovaries were bisected,
maintaining at least two periovulatory follicles greater than 4 mm in diameter on each
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piece. The pieces were covered with O.C.T. Compound (Sakura, Tokyo, Japan), frozen in
liquid propane, and stored at -80°C.

Granulosa cell culture
Monkey granulosa cells obtained before hCG administration were plated on
LabTek glass chamber slides (Nalgene Nunc, Rochester, NY) at a concentration of
20.000 cells/200 ui medium or 48 well culture plates (Corning Incorporated, Corning,
NY) at a concentration of 100,000 cells/400 ul medium. The cells were cultured on
fibronectin-coated surfaces in serum-free DMEM-Ham's F12 medium containing insulin,
transferrin, selenium, aprotinin, and human low-density lipoprotein as previously
described in Materials and Methods for specific aims #1 and #2. At the initiation of
culture, hCG (Serono; 100 ng/ml) and indomethacin (Sigma Chemical Co., St Louis,
MO; 100 nM) were added to all except the control wells. After 24 hours in vitro, one of
the following treatments was added: PGE2 (1 uM), the EP1 agonist 17 phenyl-trinor
PGE2 (10 uM), the EP2 agonist butaprost (10 uM), or the EP3 agonist sulprostone (1
uM). PGE2 and all EP receptor selective agonists were obtained from Cayman Chemicals
(Ann Arbor, MI). Cells were then maintained in vitro for an additional 4 or 12 hours,
after which the cells were either lysed with Trizol reagent (Invitrogen, Rockville, MD)
for RNA extraction or fixed with 10% buffered formalin for 30 minutes then stored at
4°C in PBS for immunofluorescent detection of tPA and PAI-1 proteins. For the same
purpose, some cells were cultured with or without 20 IU/ml hCG (Sigma) alone for 12,
24 and 36 hours, then formalin fixed. Additional granulosa cells were cultured on
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chamber slides with hCG+indomethacin for 24 or 36 h, then fixed and stored as described
above for immunofluorescent detection of EP receptors.

Real-Time RT-PCR
Levels of mRNA for tPA, uPA, and PAI-1 were assessed by real-time RT-PCR
using a Roche LightCycler (Roche Diagnostics, Indianapolis, IN, USA). Total RNA was
obtained from granulosa cells using Trizol reagent, treated with DNase and reverse
transcribed. PCR was performed using the FastStart DNA Master SYBR Green I kit
(Roche) following manufacturer's instructions and using 0.5 uM primers and 4 mM
MgCb. Primers were designed using LightCycler Probe Design software (Roche) based
on the human or monkey sequences (Table 2) and span an intron to prevent undetected
amplification of genomic DNA. PCR products were sequenced (Microchemical Core
Facility, San Diego State University, CA) to confirm amplicon identity. At least 5 log
dilutions of the sequenced PCR product were included in each assay and used to generate
a standard curve. For each sample, the content of tPA, uPA, PAI-1, and P-actin mRNA
was determined in independent assays. No amplification was observed when monkey
cDNA was omitted. All data were expressed as the ratio of mRNA of interest to P-actin
mRNA for each sample.

Immunofluorescent protein detection
Frozen ovarian tissues were sectioned at 10 urn and fixed with buffered 10%
formalin. After antigen retrieval with 10 mM sodium citrate, sections were blocked with
5% non-immune goat serum (Vector Laboratories) in PBS containing 0.1% Triton.
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Table 2. Reaction conditions for Real-Time RT-PCR for tPA, uPA. and PAI-1 mRNA.
Target

tPA
uPA
PAI-1
p-actin

Primer sequences (5'-3')

Amplified
cDNA
(bp)

Published
monkey and
human
sequences

NM000930

% identity
between
monkey
and
published
human
and
monkey
sequences
96

up: GCTACGTCTTTAAGGCG
dn: GATGCGAAACTGAGGC
up: ACCACAACGACATTGC
dn: GAGCCGTAGTAGTGGG
up:GCCATTACTACGACATCCT
dn: CGTGCCACTCTCGTTC
up: ATCCGCAAAGACCTGT
dn: GTCCGCTAGAAGCAT

365

EU427935

244

NM_002658

97

EU427936

347

NM000602

97

EU427934

270

NM_001101

97.4

AY765990

Monkey
amplified
fragment
accession
number
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Sections were then incubated for 1 hour at room temperature either with primary
antibody generated against tPA (rabbit anti-human polyclonal antibody at 4 ug/ml, Santa
Cruz Biotechnologies, Santa Cruz, CA), uPA (mouse anti-human monoclonal antibody,
15 ug/ml, Calbiochem), PAI-1 (mouse anti-human monoclonal antibody, 10 |u,g/ml,
Calbiochem), or no primary antibody, followed by incubation with Alexa Fluor 488
conjugated anti-rabbit or anti-mouse secondary antibody (4 ug/ml; Molecular Probe After
incubation with 1% Sudan Black in 70% methanol, the slides were coverslipped using
Vectashield medium (Vector Laboratories).
Formalin-fixed cultured granulosa cells were blocked with 5% non-immune goat
serum and incubated for 1 hour at room temperature with either the tPA or PAI-1 primary
antibody and Alexa Fluor 488 secondary antibody as described above. Additional
formalin-fixed cultured granulosa cells were blocked with 5% non-immune goat serum
and incubated for 1 hour at room temperature with a rabbit anti-human polyclonal
antibody against one of the following PGE2 receptors: EP1 (2 ug/ml), EP2 (10 ug/ml), or
EP3 (4 ug/ml); all EP receptor antibodies were obtained from Cayman Chemical. In
some experiments, the anti-EP receptor primary antibody was preincubated with the
respective blocking peptide at a 1:2 ratio prior to use in the primary antibody incubation
step. Immunofluorescent protein detection proceeded as described above.
All images were obtained using an Olympus BX41 fluorescent microscope fitted
with a DP70 digital camera and associated software (Olympus, Melville, NY).
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In situ zymography
PA activity was detected using modifications of previously reported methods
(365, 366). 10 jam thick frozen ovarian sections were rapidly thawed at 37°C and stained
with propidium iodide (100 ng/ml; Sigma-Aldrich, St. Louis, MO) in PBS for 1 minute.
Carnation nonfat milk powder (Nestle, Glendale, CA) was dissolved in PBS (20% w/v),
heated to 95 °C for 30 minutes and centrifuged for 5 minutes at 3000g. The supernatant
was maintained at 55°C. A 1.2% solution of agar in water was boiled for 10 minutes then
chilled to 55°C. Four parts of 1.2 % agar were mixed with one part of milk solution, and
plasminogen (75 u.g/ml; Molecular Innovations, Inc, Southfield, MI) was added. Tissue
sections were overlaid with the agar-milk-plasminogen mixture, coverslipped, and
incubated at 37°C in humidified chamber for 90 minutes. Proteolytic areas appeared as
clear, transparent zones in the opaque and cloudy overlay mixture. Ovarian sections were
then stored at 4°C until images were taken. Dark-field and fluorescent images were
obtained using an Olympus BX41 fluorescent microscope as described above.
To determine whether plasminogen was required for proteolysis, some ovarian
sections were overlaid with an agar-milk mixture lacking plasminogen. Additional
ovarian sections were pre-incubated with the anti-tPA antibody (8 ng/ml) for 10 minutes
at room temperature, after which in situ zymography was performed as described above.
In the preliminary experiments, proteolysis was monitored periodically every 30 min for
4 hours, then at 5, 7, and 20 hours in order to determine the optimal incubation time.
Proteolysis over areas containing cells was apparently complete by 90 minutes, so all data
were collected after 90-minute incubation. After 3-hour incubation, proteolytic zones
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were visible distant from the tissue section, indicating spontaneous degradation of milk
casein.

tPA and PAI-1 measurements in follicular fluid
Follicular fluid levels of total tPA and total PAI-1 were determined using
AssayMax Human tPA and AssayMax Human PAI-1 ELISA kits (AssayPro, St. Charles,
MO) according to the kit instructions. Intra-assay coefficients of variation for tPA and
PAI-1 kits were 5.7 % and 4.7 % respectively; all samples were tested within one tPA or
PAI-1 assay. The lower limit of detection (0.031 ng/ml for tPA) was used for statistical
analysis of one granulosa cell sample obtained at 0 hour hCG as tPA was not detectable
by ELISA.

Data analysis
All data were assessed for heterogeneity of variance and were log-transformed
when Bartlett's test yielded a significance of less than 0.05. Data presented in Figures
12A-C and 14B were log-transformed before further analysis. In all figures,
untransformed data are presented. Data presented in Figures 12 and 14 were assessed by
ANOVA. Levels of tPA and PAI-1 mRNA in cultured granulosa cells were assessed by
ANOVA with one repeated measure. For all ANOVAs, posthoc analyses were performed
using Duncan's multiple range test. Statistical analyses were performed using StatPak
v4.12 software (Northwest Analytical, Portland, OR). Data are presented as mean ±
SEM, and significance was assumed at p value < 0.05.
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5.2 Results for Specific Aims #3 and #4

tPA, uPA and PAI-1 expression in granulosa cells
Monkey granulosa cells expressed mRNA for tPA, uPA and PAI-1 before and
after administration of an ovulatory dose of hCG in vivo (Figure 13). Levels of tPA
mRNA were not different 0-24 hours after hCG administration, but tPA expression
decreased 36 hours after hCG to levels below those measured after 12 hours of hCG
exposure (Figure 13 A). Levels of uPA mRNA levels were low at 0 hour hCG, increased
transiently 12 hours after hCG administration, and returned to low levels 36 hours after
hCG administration (Figure 13B). PAI-1 mRNA was low at 0 hour hCG, increased 12
hours after hCG administration, and remained high for the rest of the periovulatory
period, peaking 36 hours after hCG administration (Figure 13C). The ability of hCGstimulated PGs to modulate expression of PA family members was also examined.
Administration of the PG synthesis inhibitor celecoxib with hCG for 36 hours did not
alter mRNA levels for tPA, uPA, or PAI-1 when compared with mRNA levels after
treatment with hCG alone (Figure 13). Therefore, an ovulatory dose of hCG regulated
granulosa cell levels of mRNA for these PA family members, but hCG-stimulated PGs
did not alter expression of PA family members.
PA family member proteins were localized to monkey ovarian cells using
immunofluorescence. Before hCG administration, tPA protein levels were very low in
both granulosa cells and in the ovarian stroma (Figure 14A). After treatment with hCG
for 12, 24 or 36 hours, tPA protein was easily detected in the cytoplasm of granulosa cells
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Figure 13. tPA, uPA, and PAI-1 mRNA levels in monkey granulosa cells.
Granulosa cells were obtained from monkeys experiencing controlled ovarian
stimulation before (0 hour) and 12, 24, and 36 hours after hCG administration;
additional animals received hCG and celecoxib (36+cbx) for 36 hours.
Granulosa cell levels of mRNAs were determined by real time RT-PCR; all
mRNA levels are expressed relative to P-actin mRNA. Data are presented as
mean±SEM (n=4-6 animals/time point). In panels A, B, and C, groups with
different letters are different by ANOVA and Duncan's,
pvalue<0.05.
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Figure 14. Detection of tPA and PAI-1 proteins and PA proteolytic activity in the
monkey periovulatory follicles. Ovaries were obtained from monkeys experiencing
controlled ovarian stimulation as described in the legend for Figure 1.
Immunodetection (bright green) of tPA (A-E) and PAI-1 (F-J) is shown after
treatment with hCG for 0 (A, F), 12 (B, G), 24 (C, H), or 36 (D, I) hours, or with
hCG+celecoxib for 36 hours (E, J). Sections are not counterstained. For panels AJ, use bar in panel E=100 um. There was no detectable immunofluorescence when
the primary antibody for tPA (D inset) or PAI-1 (I inset) was omitted. In situ
zymography was performed using ovarian sections obtained after treatment with
hCG for 0 (K), 12 (L), 24 (M), or 36 (N) hours, or with hCG+celecoxib for 36
hours (O). In all panels, propidium iodide staining of cell nuclei appears red.
Undegraded casein protein is detectable as greenish cloudy spots; casein is absent
in the areas of proteolysis (black or spot-free areas indicated by white arrows). No
proteolysis was observed when plasminogen was omitted from the overlay mixture
(P) or when tissues were pre-incubated with the anti-tPA antibody (Q). Milk casein
was captured on dark field images whereas cell nuclei were visible under the
fluorescent light. All panels are composites of dark field and fluorescent images of

ovarian sections. In each periovulatory follicle shown, the antrum (a) is in the
upper right, granulosa cells (gc) are central, and the ovarian stroma (s) is in the
lower left portion of the image. For panels K-Q, bar in panel 0=400 um. All
ovarian images, except panels P and Q, are representative of 3 animals/time point.
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and, to a lesser extent, in the ovarian stroma (Figure 14B-D). uPA protein was low to
undetectable in granulosa cells and the ovarian stroma at all times examined (Appendix 6
and data not shown). However, uPA was present in the endothelial cells of large blood
vessels located in the ovarian stroma and in kidney, which served as a positive control.
PAI-1 protein was low to undetectable in granulosa cells and the ovarian stroma
before hCG administration (Figure 14F). However, PAI-1 protein was easily detected in
the cytoplasm of granulosa cells of ovaries obtained 12, 24 and 36 hours after hCG
administration (Figure 14G-I). Treatment with hCG+celecoxib for 36 hours reduced both
tPA and PAI-1 proteins to very low levels when compared with tPA and PAI-1 protein
detection in granulosa cells of monkeys treated with hCG only (Figure 14E, J).
Immunofluorescence was absent when the primary antibodies for tPA and PAI-1 were
omitted, serving as a negative control (Figure 14D, I insets). Therefore, tPA and PAI-1,
but not uPA, proteins were present in the granulosa cells of monkey periovulatory
follicles. Levels of tPA and PAI-1 protein increased in response to an ovulatory dose of
hCG, but continued expression was eliminated by the PG synthesis inhibitor celecoxib.
To confirm that hCG upregulates granulosa cell expression of tPA and PAI-1
proteins, granulosa cells obtained before hCG administration were cultured without
(control) or with an ovulatory dose of hCG for 12, 24 and 36 hours. tPA
immunodetection was very low in controls (Appendix 6A-C) but increased tPA protein
expression was present in the cells that were treated with hCG for 12, 24 and 36 hours
(Appendix 6D-F). Similarly, hCG increased PAI-1 protein expression over the controls at
all times examined (Appendix 6G-L).
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In situ Zymography for PA activity in the monkey periovulatory follicle
Detection of PA activity utilized the concept that PA family members convert
inactive plasminogen to the active protease plasmin, which can digest the milk protein
casein. To identify regions of ovarian follicles that contained PA activity, tissue sections
were overlaid with a mixture containing both plasminogen and casein. Intact casein
appeared as a greenish cloudy or spotty substance (Figure 14K); proteolysis was detected
as dark regions which were cleared of the cloudy or spotty material (Figure 14L-N).
Omission of plasminogen from the overlay mixture deprived the reaction of this essential
proenzyme, and no proteolysis was observed (Figure 14P), demonstrating that this
technique specifically detected PA-dependent proteolytic activity.
Ovarian tissues obtained before administration of an ovulatory dose of hCG did
not contain sufficient PA proteolytic activity to degrade the casein present in the overlay
mixture (Figure 14K). In contrast, vast zones of proteolysis were observed over and
around granulosa cells of ovaries obtained 12, 24, and 36 hours after hCG (Figure 14LN). Proteolytic activity was absent over ovarian sections obtained from animals treated
for 36 hours with hCG and celecoxib (Figure 140). Importantly, pre-incubation of tissue
sections with the anti-tPA antibody essentially eliminated proteolysis around granulosa
cells (Figure 14Q), supporting the conclusion that PA activity in monkey periovulatory
follicle is catalyzed mainly by tPA. Therefore, exposure to an ovulatory dose of hCG
increased granulosa cell tPA activity, and this increase in PA activity in the late
periovulatory period was dependent on ovarian PG production.
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tPA and PAI-1 protein levels in follicular fluid
Secreted tPA and PAI-1 were examined by assessment of PA family members in
monkey follicular fluid. Levels of tPA in follicular fluid were low before hCG, increased
to reach peak levels 24 hours after hCG administration, and returned to intermediate

levels 36 hours after hCG (Figure 15A). PAI-1 levels in follicular fluid were low before
hCG, increased 12 hours after hCG administration, and remained high for the rest of the
periovulatory period (Figure 15B). Therefore, levels of tPA and PAI-1 proteins in
follicular fluid increased in response to hCG administration, similar to hCG-regulated
changes in tPA and PAI-1 proteins detected in granulosa cells by immunofluorescence.

tPA and PAI-1 protein expression in cultured granulosa cells
Inhibition of PG synthesis within the periovulatory follicle prevented follicle
rupture, while intrafollicular injection of PGE2 restored follicle rupture in inhibitortreated monkeys (96). PGE2 levels in monkey follicular fluid were very low 0 and 12
hours after hCG administration; PGE2 levels increased 24 hours after hCG and peaked at
36 hours after hCG (99). Therefore, key actions of PGE2 are anticipated to occur late in
the periovulatory interval. While celecoxib treatment in vivo reduces intrafollicular PGE2
levels (364), this COX-2 inhibitor likely blocks production of many eicosanoids within
the monkey follicle. Further experiments were necessary to identify the unique role of
PGE2 in the regulation of granulosa cell tPA and PAI-1 expression.
To determine if hCG alone or hCG-stimulated PGE2 regulates granulosa cell tPA
and PAI-1 expression, a cell culture model was developed to mimic in vivo periovulatory
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Figure 15. tPA and PAI-1 protein levels in follicular
fluid. Aspiration of follicular fluids was performed
on monkeys experiencing controlled ovarian
stimulation before (0) and 12, 24, and 36 hours after
hCG administration. tPA and PAI-1 proteins were
measured by ELISA. Data are presented as
mean±SEM (n=4-5 animals/time point). In panels A
and B, groups with different letters are different by
ANOVA and Duncan's, p value<0.05.
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events (Figure 16). Cells obtained from large, preovulatory follicles before hCG were
maintained in vitro with an ovulatory dose of hCG; the general COX inhibitor
indomethacin was also included in culture medium to inhibit endogenous PG production.
After 24 hours of culture, PGE2 (or an EP receptor selective agonist) was added to some
cultures to simulate the rise in follicular fluid PGE2 which occurs 24 hours after hCG
administration in vivo. Cells were then cultured for an additional 4 or 12 hours, for a total
of 28 or 36 hours in vitro, to examine the effects of short-term or long-term PGE2
exposure, respectively.
Granulosa cells cultured for a total of either 28 and 36 hours with no treatment
(control), hCG+indomethacin, hCG+indomethacin+PGE2, or hCG+indomethacin+an EP
receptor selective agonist were assessed for tPA and PAI-1 mRNA levels (Appendix 7).
Neither tPA nor PAI-1 mRNA levels differed between treatment groups at either time
examined. This is similar to our findings obtained from monkey granulosa cells treated
with hCG alone or hCG+celecoxib in vivo, where no differences were observed between
tPA or PAI-1 mRNA levels in granulosa cells obtained late in the periovulatory interval
in the absence or presence of this PG synthesis inhibitor (Figure 13).
Protein expression of tPA was assessed by immunofluorescence in granulosa cells
cultured as described above. Granulosa cells cultured for 28 hours with no treatment
(Figure 17 A) or with hCG+indomethacin (Figure 17B) showed very low levels of tPA
protein. In granulosa cells that received PGE2 for the final 4 hours during a total of 28
hours in vitro with hCG+indomethacin (Figure 17C), tPA protein was apparently more
abundant. tPA protein detection was very low in granulosa cells that received EP1
receptor agonist 17 phenyl-trinor PGE2 instead of PGE2 (Figure 17D). In contrast,

108

0

24

28

36
(hours)

Control (no treatment) _ _ _ _ _ _ _ _ _ _ _ _

_ l _ _ _

hCG+lndomethacin

'

'

hCG+lndomethacin
»
+PGE2 or EP agonist

I

t
I

I

i.

Figure 16. Cell culture model to mimic in vivo periovulatory
events. Cells obtained from large, preovulatory follicles before
hCG were maintained in vitro either with no treatment (Control)
or with an ovulatory dose of hCG plus the general COX inhibitor
indomethacin included in culture medium to inhibit endogenous
PG production (hCG+lndomethacin). After 24 hours of culture,
PGE2 or an EP receptor selective agonist was added to some
cultures (hCG+Indomethacin+PGE2 or EP agonist) to simulate
the rise in follicular fluid PGE2, which occurs 24 hours after hCG
administration in vivo. Cells were harvested after additional 4 or
12 hours of culture, for a total of 28 or 36 hours in vitro, to
examine the effects of short-term or long-term PGE2 exposure,
respectively.
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Figure 17. Immunofluorescent detection of tPA and PAI-1
proteins in cultured granulosa cells. Granulosa cells obtained
from animals undergoing controlled ovarian stimulation before
hCG administration were maintained in vitro with no treatment
(A, G) or with hCG+indomethacin (B-F, H-L). After 24 hours,
some cultures received additional treatment: PGE2 (C, I), 17
phenyl-trinor PGE2 (D, J), butaprost (E, K), or sulprostone (F,
L). Cells were cultured for a total of 28 hours for
immunodetection of tPA (A-F) or 36 hours for
immunodetection of PAI-1 (G-L). Immunodetection appears
green; nuclei are counterstained red. All images are
representative of 4 animals/treatment. For all images, use bar in
panel A=20 urn.
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intense tPA immunofluorescence was present in granulosa cells treated with either the
EP2 receptor agonist butaprost or the EP3 receptor agonist sulprostone (Figure 17E, F).
PGE2, butaprost, and sulprostone (but not 17 phenyl-trinor PGE2) also increased
immunofluorescent detection of tPA protein in granulosa cells cultured for a total of 36
hours (data not shown).
PAI-1 protein was low/non detectable in granulosa cells cultured for 28 hours
with no treatment, hCG+indomethacin, hCG+indomethacin+PGE2, or
hCG+indomethacin+any EP receptor selective agonist (data not shown). Cells cultured
for 36 hours with no additional treatment (Figure 17G) or with hCG+indomethacin
(Figure 17H) showed very low levels of PAI-1 protein. PAI-1 immunofluorescence was
more abundant in granulosa cells that received PGE2 during the final 12 hours during a
total of 36 hours in vitro (Figure 171). Treatment with either the EP1 receptor agonist 17
phenyl-trinor PGE2 or the EP3 receptor agonist sulprostone increased PAI-1
immunofluorescence (Figure 17J, L), similar to PAI-1 levels observed in granulosa cells
treated with PGE2. In contrast, PAI-1 immunofluorescence was very low or absent in
granulosa cells treated with the EP2 receptor agonist butaprost (Figure 17K). Neither tPA
nor PAI-1 was detected when the primary antibody was omitted (data not shown).
To determine if EP receptors were available to mediate the effects of PGE2 or EP
receptor selective agonists in vitro, immunofluorescent detection of EP receptor proteins
was performed. EP1, EP2, and EP3 proteins were present in granulosa cells cultured with
hCG+indomethacin for 24 and 36 hours (Appendix 8A-C and data not shown). No EP
receptor immunostaining was observed when the primary antibodies were pre-incubated
with the respective blocking peptide (Appendix 8D-F).
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5.3 Discussion for Specific Aims #3 and #4

This study is the first to demonstrate that gonadotropin regulation of PA activity
in the periovulatory follicle is mediated via PGE2. In vivo, granulosa cell tPA and PAI-1
protein expression as well as PA proteolytic activity increased in response to
administration of an ovulatory dose of gonadotropin. However, maintenance of tPA and
PAI-1 protein levels as well as PA activity requires PG synthesis in the late periovulatory
period. PGE2 has previously been identified as the key PG involved in ovulation in many
species (41, 367), including monkeys (96). While defects in follicle rupture consistently
occur when follicular PG synthesis is inhibited, the specific mechanism by which
elevated intrafollicular PGE2 promotes ovulation is unknown. This investigation presents
novel data which demonstrate that PGs are required to maintain PA proteolytic activity
late in the periovulatory interval. Granulosa cell levels of tPA and PAI-1 are regulated via
PGE2 (EP) receptors, confirming that PGE2 is involved in periovulatory regulation of PA
family components. Different EP receptors mediate the ability of PGE2 to regulate
expression of tPA and PAI-1. EP receptor selective agonists and antagonists may be
useful to promote or inhibit follicular proteolysis by independently controlling the
expression and activities of members of the PA system.
Expression of the components of the PA system increased in response to the
ovulatory gonadotropin surge. In the present study, we used a combination of techniques
to demonstrate that hCG increased levels of tPA and PAI-1 proteins in both granulosa
cells and follicular fluid in monkey periovulatory follicles. Previous studies focused on
measurement of secreted PA family member proteins (216, 309. 318, 319, 322, 368).
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Follicular fluid and conditioned media from cultures of follicular cells and were assessed
for levels of PA family member proteins, but gonadotropin regulation of synthesis of PA
family member proteins in vivo was not directly addressed (216, 309, 318, 322, 368). In
the present study, granulosa cells were identified as the primary site of tPA and PAI-1
synthesis in periovulatory follicles of cynomolgus macaques. These findings contrast
with a report identifying theca, but not granulosa, cells as the primary site of PAI-1
synthesis in the rhesus monkey follicle (319). However, this study relied on primary
cultures of theca and granulosa cells and did not confirm the presence of PAI-1 protein in
specific cell types in ovarian tissue sections. While tPA was consistently detected in
monkey follicles, uPA protein was not detected, despite the presence of uPA mRNA in
monkey granulosa cells. The presence of uPA in the endothelium of the ovarian blood
vessels suggests a possible role in vascular remodeling, but tPA is likely the predominant
PA enzyme involved in proteolysis of the follicle wall. While previous studies focused
on the ability of the ovulatory gonadotropin surge to increase levels of secreted proteins,
the present study demonstrates that hCG increases granulosa cell tPA and PAI-1 protein
levels, implicating hCG as a primary stimulus for synthesis of these important proteins.
Earlier studies have shown that gonadotropin regulates mRNA levels of PAs and
their inhibitors in ovarian follicles (312, 318, 369, 370). Although human periovulatory
granulosa cells were shown to express abundant amounts of PAI-1 mRNA but not mRNA
for tPA or uPA (371), our study used more sensitive RT-PCR to detect measurable tPA,
uPA and PAI-1 mRNA in monkey granulosa cells obtained throughout the periovulatory
period. In addition, human granulosa cells were collected from women undergoing in
vitro fertilization, so aspirates were collected only late in the periovulatory period when,
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as we have shown, uPA and tPA mRNAs are very low while PAI-1 mRNA expression
was highest. Most importantly, mRNA levels for tPA and PAI-1 did not correlate with
changing protein levels in the present study, suggesting that the expression of PA family
members is regulated primarily at a post-transcriptional level. Assessment of protein
levels and, ideally, activity will be required to understand how PA family members are
regulated and how these key proteins contribute to proteolytic events necessary for
ovulation.
The ovulatory gonadotropin surge induced changes in proteolytic activity in the
follicle wall during the periovulatory period. In situ zymography was used to demonstrate
the presence of proteolytic activity primarily around granulosa cells in monkey
periovulatory follicles. Omission of plasminogen confirmed that the observed proteolysis
was mediated by a member of the PA family. Proteolysis detected by in situ zymography
correlated with levels of tPA protein observed in granulosa cells by immunofluorescence,
with little protein or proteolysis observed in ovaries obtained before (0 hour) hCG and
abundant protein and proteolysis observed at all times after hCG administration.
Pretreatment of ovarian tissues with an anti-tPA antibody essentially eliminated
plasminogen-dependent proteolytic activity around granulosa cells, again supporting
identification of tPA, but not uPA, as the active PA in the periovulatory follicle. Previous
studies provide indirect evidence of tPA regulation by gonadotropins. In rat and monkey
granulosa cells, gonadotropin exposure in vivo increased tPA activity in conditioned
medium obtained from granulosa cell cultures (216, 319). Perhaps most interesting is a
study by Dow and colleagues, where the apex and base of periovulatory follicles were
dissected free, and homogenates were subjected to gel zymography for tPA and uPA
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activity (372). While an ovulatory dose of gonadotropin increased tPA and uPA activity
in both apical and basal homogenates, similar levels of proteolytic activity were
measured in these regions, suggesting that PA-mediated proteolysis is not restricted to the
follicle apex and may occur around the entire perimeter of the follicle at ovulation. Work
by Murdoch and colleagues has suggested that the ovarian surface epithelium secretes
uPA via the basolateral membrane (373), so PA activity provided by the surface
epithelium may well determine the actual location of the follicle apex via PA proteolytic
activity. The presence of PA-mediated proteolysis around the entire follicle also suggests
that the PA system may be involved in the structural remodeling and neovascularization
necessary for both ovulation and corpus luteum formation.
In situ zymography showed that the gonadotropin-stimulated increase in tPA
activity occurred despite the concomitant increase in the PAI-1 protein expression. In our
cynomolgus macaques, PAI-1 protein was present at low levels in ovaries obtained
before hCG; PAI-1 protein was easily detected in granulosa cells at all times after hCG
administration. Plasminogen- and tPA-dependent proteolysis began as early as 12 hours
after hCG administration and continued throughout the periovulatory period, so hCG
administration increased follicular tPA activity in parallel with rising tPA and PAI-1
proteins. As a member of the serpin family, PAI-1 inhibits PA activity by mimicking the
substrate and trapping the enzyme in an inactive stable 1:1 complex (285). The observed
gonadotropin-stimulated increase in proteolytic activity indicates that at least a portion of
the tPA induced by gonadotropin stimulation was unopposed by PAI-1. Parallel
regulation of a proteolytic enzyme and its inhibitor as described in this study has also
been reported for matrix metal!oproteases and their tissue inhibitors (225, 248, 279). This
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type of parallel regulation may prevent uncontrolled proteolysis by limiting the site
and/or extent of proteolytic degradation.
Evidence from several studies supports the hypothesis that gonadotropin
regulation of PA-mediated proteolysis in the follicle requires ovarian PG synthesis.
Studies in rat have shown that in vitro the general COX inhibitor indomethacin inhibits
gonadotropin-stimulated granulosa cell fibrinolytic activity, while PGs alone or in
combination with LH induce fibrinolytic activity in granulosa cell conditioned media
(216, 309, 322, 374). The activity of tPA, as measured by gel zymography in follicular
fluid and homogenates of ovarian follicular apex tissue, was inhibited by indomethacin
treatment in the cow (318). While these studies support a role for COX-mediated PG
synthesis to regulate PA family member proteins and PA-mediated proteolytic activity in
ovarian tissues, the specific PG involved has not been identified.
Our in vitro studies support the hypothesis that PGE2 is the biologically active
prostanoid important for the maintenance of ovulatory PA activity. In the non-human
primate, PGE2 levels increase 24 hours after hCG administration and peak just before the
expected time of ovulation (99). In vivo, elevated PGE2 levels in the late periovulatory
period maintained tPA and PAI-1 expression and PA proteolytic activity, whereas PG
synthesis inhibition with celecoxib greatly inhibited the expression of PA family member
proteins as well as tPA dependent proteolytic activity. For in vitro studies, cultures of
granulosa cells were treated to simulate this window of PGE2 exposure, which occurs
late in the periovulatory period in vivo. To inhibit the production of all bioactive PGs in
granulosa cell cultures, indomethacin was included with an ovulatory dose of hCG; 24
hours later, PGE2 or an EP receptor selective agonist was added to examine the effect on
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the expression of tPA and PAI-1. Similar to in vivo results, hCG alone was not able to
maintain granulosa cell levels of tPA and PAI-1 proteins after 28 or 36 hours in vitro. In
contrast, PGE2 maintained tPA and PAI-1 protein levels, confirming a key role for this
specific prostanoid in plasminogen dependent proteolysis in the follicle wall.
Perhaps the most important and novel result of our in vitro studies was the
demonstration that different subsets of PGE2 receptors were required to maintain tPA and
PAI-1 protein expression. PGE2 can act through 4 G protein coupled receptors: EP1,
EP2, EP3, and EP4 (360, 375). In a previous study, we demonstrated that monkey
granulosa cells express functional EP1, EP2, and EP3 receptors; granulosa cell
expression and responsiveness of all three EP receptors peaked just before the expected
time of ovulation (376). In order to identify the EP receptors through which PGE2
regulates PA components, EP receptor selective agonists were used to stimulate
individual EP receptors in granulosa cell cultures. Activation of EP2 and EP3 receptors
increased tPA protein levels. Both EP2 and EP3 can increase intracellular cAMP by
coupling to Gas (148), suggesting a common mechanism of action to regulate granulosa
cell levels of tPA protein. In contrast, PAI-1 protein expression was increased by
stimulation of EP1 and EP3 receptors, each of which can couple to Gaq to regulate
additional intracellular signaling pathways (114). Further studies will be required to
identify the specific intracellular signaling pathways responsible for regulation of tPA
and PAI-1 expression. These novel studies indicate that tPA and PAI-1 expression and
activity can be independently regulated via different PGE2 receptors. Therefore, drugs
which bind to a single EP receptor may be useful to selectively stimulate proteolysis of
the follicle wall via EP2 or selectively inhibit follicular proteolysis via EP1. By
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identifying EP receptors which regulate specific proteins involved in ovarian proteolysis,
this study identifies new targets for drug therapies to either promote or prevent ovulation.
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SECTION 6
SUMMARY

High intrafollicular PGE2 levels right before expected time of ovulation and the
inability of follicles to rupture and release the oocyte in the absence of PG synthesis led
to the hypothesis that PGE2 plays an essential ovulatory role in the late periovulatory
period, most probably to facilitate the proteolytic degradation of the follicle wall. To
elucidate the role of PGE2 in primate ovulation, the expression and function of EP
receptors as well as their involvement in the regulation of the components of PA/plasmin
system were studied in primate periovulatory granulosa cells.
From these studies the following conclusions were made:
Specific Aim #1: Three out of four EP receptors (EP1, EP2, and EP3) are expressed in
periovulatory granulosa cells. The expression of these receptor proteins is regulated by
the ovulatory gonadotropin surge to achieve peak EP receptor levels before the expected
time of ovulation.
Specific Aim #2: In the late periovulatory period, the ability of EP2 and EP3 receptors to
stimulate cAMP production and the ability of the EP1 receptor to increase [Ca2+]i are
increased in response to an ovulatory dose of gonadotropin, such that maximal second
messenger generation occurs with peak follicular PGE2 levels.
Specific Aim #3: The ovulatory gonadotropin surge induces plasminogen dependent
proteolysis in the primate periovulatory follicle. However, late in the periovulatory
period, hCG alone is unable to maintain the maximal proteolytic activity required for the
degradation of follicle wall. In the final hours proceeding ovulation, PGs are necessary
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for the expression of tPA and PAI-1 proteins and, hence, for the maintenance of
plasminogen dependent proteolysis.
Specific Aim #4: Experiments on the cultured granulosa cells show that PGE2, acting via
different EP receptor subsets, regulates the expression of tPA and PAI-1 proteins. The
data supports the hypothesis that one specific ovulatory action of PGE2 is to facilitate
proteolytic degradation of the follicle wall.

Identification of PGE2 and the specific EP receptors involved in the regulation of
ovarian proteolysis provides new targets for the development of drugs to promote
ovulation and treat some cases of infertility, or to prevent ovulation and achieve
contraception without alteration of circulating levels of ovarian steroid hormones.
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Figure 18. cAMP production by monkey periovulatory granulosa
cells in response to treatment with different doses of PGE2.
Granulosa cells were obtained from monkeys experiencing
controlled ovarian stimulation 36 hours after hCG administration and
plated 20,000 cells/well in 200 ul medium. The cells were incubated
for 16 hours with no PGE2 (0) or with PGE2 at 0.01 uM, 0.1 uM,
and 1 uM concentrations (n=2). Media cAMP was measured by
enzyme immunoassay and normalized to the protein content of the
wells. Data are presented as mean±SEM (n=2 animal/dose of
treatment).
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Figure 19. cAMP accumulation in
granulosa cell culture media in response
to PGE2 treatment. Granulosa cells
were obtained from monkeys
experiencing controlled ovarian
stimulation 24 (n=l) or 36 (n=2) hours
after hCG administration and plated
20,000 cells/well in 200 ul medium.
The cells were incubated with PGE2 for
4, 10, 16, and 24 hours. Media cAMP
was measured by enzyme immunoassay
and normalized to the protein content of
the well. Data are presented as
mean±SEM (n=2-3 animal/time point).
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Figure 20. Western blotting for EP2 and EP3 receptors with primary
antibodies pre-incubated with antibody blocking peptides. Lysates containing
20 ug of protein from monkey periovulatory granulosa cells (lanes 1, 4, 8,
and 11), human periovulatory granulosa cells (lanes 2, 5, 9, and 12), and
monkey kidney (lanes 3, 6, 10, and 13) were analyzed by western blotting.
Membranes were incubated with antibodies against EP2 (lanes 1, 2, and 3)
and EP3 (lanes 8, 9, 10), or with anti-EP2 antibody+blocking peptide (lanes
4, 5, 6) and anti-EP3 antibody+blocking peptide (lanes 11, 12, 13). For lanes
4-6 and 11-13 anti-EP2 and anti-EP3 antibodies were pre-incubated with
respective blocking peptides in 1:2 ratio for 1 hour at room temperature.

APPENDIX 4

Figure 21. Immunofluorescent detection of EP receptors in
monkey granulosa cells. Ovaries were obtained from monkeys
experiencing spontaneous menstrual cycles before expected
time of endogenous LH surge (A, D, G, and J), the day of LH
surge (B, E, H, and K), and 2 days after LH surge (C, F, I, and
L). In each periovulatory follicle shown, the antrum (a) is in
the upper right, granulosa cell (gc) are central, and the ovarian
stroma (s) is in the lower left portion of the image,
immunodetection (bright green) of EP1 (A, B , C), EP2 (D, E,

F), EP3 (G, H, I), and EP4 (J, K, L) in periovulatory follicles
is shown. No fluorescence was observed when the primary
antibodies were preabsorbed with the blocking peptide (C, F,
I, L insets). Ovarian images shown are representative of 2-3
animals/time point. For all panels, bar=50 |im.

Appendix 5

Figure 22. Detection of uPA protein in monkey
periovulatory follicles and kidney. Ovaries were obtained
from monkeys experiencing controlled ovarian stimulation.
Immunodetection (bright green) of uPA in monkey ovary
(A, B) is shown after 0 hour (A) and 36 hours (B) of
exposure to hCG in vivo. Monkey kidney tissue sections (C)
were used as positive control. For both ovary and kidney,
uPA protein was detectable in the walls of blood vessels (v).
For panels A and B the orientation of the ovarian stroma (s),
granulosa cells (gc), and the antrum (a) is the same. For all
panels, bar in panel A=400 urn. Ovarian images are
representative of 3 animals/time point.
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Figure 23. Immunofluorescent detection of tPA and PAI-1 proteins in cultured
granulosa cells. Granulosa cells obtained from animals undergoing controlled
ovarian stimulation before hCG administration were maintained in vitro with no
treatment (A-C and G-I) or with hCG (D-F and J-L). After 12 (A, D, G, and J),
24 (B, E, H, and K), and 36 (C, F, I, and L) hours in culture the cells were

formalin fixed and analyzed for immunofluorescent detection of tPA (A-F) and
PAI-1 (G-L) proteins. Immunodetection appears green; nuclei are counterstained
red. All images are representative of 4-5 animals/treatment. For all images, use
bar in panel A=20 um.
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Figure 24. tPA and PAI-1 mRNA in cultured
periovulatory granulosa cells. Granulosa cells obtained
before hCG administration were cultured without
(control) or with hCG+indomethacin. After 24 hours,
PGE2 or EP receptor selective agonists were added and
the cells were cultured for additional 12 hours. tPA (A)
and PAI-1 (B) mRNA levels were determined by real
time RT-PCR. The ratio of tPA and PAI-1 mRNA to pactin mRNA was calculated for all samples. Data
presented show the mRNA levels in treated cells relative
to controls (n=4-5/treatment group). In panel A, groups
with different letters are different by ANOVA and
Duncan's, p value<0.05.
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Figure 25. Immunofluorescent detection of EP1, EP2,
and EP3 receptors in cultured monkey granulosa cells.
Granulosa cells obtained before hCG administration (0
hour) were cultured with hCG+indomethacin for 36
hours. Immunofluorescent analysis was performed with
antibodies against EP1 (A), EP2 (B), and EP3 (C). EP
receptor immunodetection appears as bright green
staining around nuclei stained red with propidium iodide.
EP receptor detection was absent when primary
antibodies against EP1 (D), EP2 (E), and EP3 (F) were
pre-incubated with respective blocking peptides. For all
images, use bar in panel A=20 urn.
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APPENDIX 9
LIST OF COMMON ABBREVIATIONS USED
AA
ADAMTS
cAMP
[Ca2+]i
CL
COX
ECM
FSH
GDP
GnRH
GTP
hCG
IP3
kb
kDa
LH
MMP
NSAID
PA
PAI
PBS
PG
PGDH
PGE2
PGES
PGF2a
PKA
PKC
PLA2
PLC
PMSG
PCR
RT
TIMP
tPA
uPA

Arachidonic Acid
A Desintegrin and Metalloprotease Domain with
Thrombospondin Motifs
Cyclic Adenosin Monophosphate
Intracellular Ca2+ concentration
Corpus Luteum
Cyclooxygenase
Extracellular Matrix
Follicle Stimulating Hormone
Guanosine Diphosphate
Gonadotropin Realising Hormone
Guanosine Triphosphate
Human Chorionic Gonadotropin
Inositol Trisphosphate
Kilobase
KiloDalton
Luteinizing Hormone
Matrix Metalloprotease
Non Steroidal Anti Inflammatory Drug
Plasminogen Activator
Plasminogen Activator Inhibitor
Phosphate Buffered Saline
Prostaglandin
Prostaglandin Dehydrogenase
Prostaglandin E2
Prostaglandin E Synthase
Prostaglandin F 2a
Protein Kinase A
Protein Kinase C
Phospholipase A2
Phospholipase C
Pregnant Mare Serum Gonadotropin
Polymerase Chain Reaction
Reverse Transcription

Tissue Inhibitor of Matrix Metalloproteases
Tissue Type Plasminogen Activator
Urokinase Type Plasminogen Activator

152

VITA

Nune Markosyan was born in Yerevan, Armenia and completed her secondary education
there. She received her Doctor of Medicine degree from Yerevan State Medical School in June
1983. After the internship at the State Hospital of Republic, she completed her post-graduate
training at the Institute of Continued Medical Training.
In 1985-1993, Nune worked as a physician at the State Hospital of Republic in
the Department of Clinical and Laboratory Diagnostics. Her responsibilities included
review of clinical diagnoses, development of diagnostics criteria and protocols.
In 2002, Nune began the Biomedical Sciences Ph.D program under the mentorship of Dr.
Diane Duffy. During her graduate studies, Nune presented papers at national and
meetings and is a member of Endocrine Society and Society for the Study of
Reproduction.

